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The human immunodeficiency virus (HIV-1) is a well-recognized threat to global public health, 
with current estimates of ~37 million infected individuals worldwide [1]. While efforts to 
develop an effective vaccine to prevent infection have not come to fruition, several FDA 
approved drugs targeting HIV-1 have proven effective in reducing viral replication and 
improving quality of life [2]. Yet, due to the increasing emergence of drug resistant variants, new 
HIV-1 treatments are needed as the virus continues to evolve. Structure-based drug design is a 
powerful approach for facilitating the development of new HIV-1 inhibitors [3], driven mainly 
by x-ray crystallographic studies of viral proteins [4]. However, the static nature of 
crystallographic studies necessitate complementary structural and dynamic studies to genuinely 
understand protein-ligand interactions. In this thesis, solution NMR is used to investigate HIV-1 
RT, a major therapeutic target in the fight against HIV-1 infection. HIV-1 reverse transcriptase 
produces viral DNA from genomic RNA and is essential for the viral lifecycle [5]. Although the 
structure of the mature heterodimer has been well characterized, less is known about RT 
maturation from its p66 immature precursor, which so far has resisted crystallization.  I used 
NMR to investigate RT maturation and to elucidate RT interactions with FDA approved 
inhibitors. Together the results of my thesis contribute to arrive at a more comprehensive 
understanding of RT maturation and RT-inhibitor interactions. 
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1.0  INTRODUCTION 
1.1 HIV-1 
HIV-1 targets cells in the human immune system, increasing an individual’s susceptibility to 
infections and some types of cancers [1]. The most advanced phase of HIV-1 infection is referred 
to as Acquired Immunodeficiency Syndrome (AIDS). As of 2014, the World Health 
Organization estimates that HIV-1 has claimed over 34 million lives, and ~37 million people are 
currently infected with HIV-1. Therefore, the HIV-1 pandemic continues to be a global health 
issue [1]. In response, over the past 25 years, numerous multidisciplinary studies on the HIV-1 
virus have been carried out, resulting in a large breadth of knowledge about the virus. HIV-1 
belongs to the Retroviridae viral family, which comprises enveloped viruses containing RNA 
genomes [1]. HIV-1 targets cells expressing the CD4 receptor and the chemokine receptors 
CCR5 or CXCR4, including macrophages and CD4+ T cells (Figure 1.1a) [6]. The fusion of 
viral and host cell membranes is mediated by the interaction between the viral Env glycoprotein 
complex and the host cell CD4 receptors [7].  
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Figure 1.1 Schematic diagram of the HIV-1 life cycle and the organization of the HIV-1 genome 
a) HIV-1 viral replication can not occur in isolation. Therefore, the HIV-1 virus relies on the ability to 
hijack a host cell’s molecular machinery to replicate. The HIV-1 life cycle begins with the fusion of the 
viral and host membrane and the subsequent release of the capsid into the host cell’s cytoplasm. Once 
inside the cell, the single stranded RNA viral genome is converted into double stranded proviral DNA and 
then shuttled into the nucleus. After the proviral DNA is integrated into the host chromosome, the host’s 
molecular machinery produces numerous copies of viral RNA. Viral RNA transcripts can be either 
translated into viral proteins or directly packaged into progeny viruses. After packaging and viral 
detachment, PR cleaves Gag and Gag-Pol polyproteins, causing morphological changes to produce a 
mature virus. The newly produced virus can then infect neighboring cells and produce more progeny 
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viruses by reiterating through the HIV-1 life cycle (figure inspired by [8] and [9]). b) Schematic 
representation of the proteins coded by the HIV-1 genome (adapted from [10]).  
 
Once the viral and host membranes are fused, the cone-shaped capsid core is released 
into the host cell cytoplasm. The capsid is composed of capsid protein (CA), which oligomerizes 
into hexamers and a few pentamers, [11] and surrounds the viral components, including the 
mature enzymes integrase (IN), protease (PR) and reverse transcriptase (RT), and the RNA 
genome. While still in the cytosol, RT produces double stranded DNA using genomic viral RNA 
as the template. Then, the viral DNA associates with other proteins to form a nucleoprotein 
complex, which is subsequently shuttled through the nuclear pore with the aid of Vpr, a viral 
accessory protein with no enzymatic activity[11]. Inside the nucleus, the viral genome is 
integrated into the host chromosome by IN-mediated DNA processing and strand transfer, in 
conjunction with host cell enzymes that are hijacked for the subsequent steps in DNA 
integration. Once the viral DNA is covalently inserted into the host’s chromosome, the host’s 
molecular machinery produces numerous copies of the viral RNA that can be directly packaged 
into progeny viruses or translated into viral proteins [12].  
In the nucleus, the viral RNA transcripts are processed by splicing to generate various 
protein-encoding mRNAs. The structural proteins, Gag and Gag-Pol are produced from 
unspliced mRNA, while the viral proteins proteins Vif, Vpu, Vpr, and Env are produced from 
singly spliced mRNA, and Tat, Rev and Nef are produced from multi-spliced mRNA [6, 12, 13]. 
All viral proteins have distinct roles in the lifecycle. Tat upregulates viral RNA transcription by 
interacting with host cell elongations factors and RNA polymerase II (RNAP II), increasing 
RNAP II processivity and, consequently, the production of viral RNA by ~100 fold. Rev helps 
facilitate the transport of the singly spliced and unspliced viral RNA transcripts out of the 
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nucleus to the cytoplasm for translation and packaging [14]. Vif protects progeny viral DNA 
from damage by mediating the degradation of apolipoprotein B mRNA-editing enzyme-catalytic 
polypeptide-like 3G (APOBEC3G), a host immune surveillance protein that introduces hyper-
mutations into the viral DNA by catalyzing the deamination of deoxycytidine to deoxyuridine 
[10, 15, 16]. 
The structural proteins Env, Gag and Gag-Pol also play distinct roles in the viral 
lifecycle. The env gene codes for the gp160 precursor, which is cleaved to produce the Env 
proteins gp120 and gp41. The Env proteins are shuttled to the host cell plasma membrane 
through the secretory pathway, via the rough endoplasmic reticulum and golgi.  In mature virons, 
gp120 and gp41 proteins associate non-covalently to form trimeric structures, which sparsely 
stud the viral envelope. The Env glycoprotein complex is the main target for host cell antibodies; 
however, heavy glycosylation conceals surface epitopes, allowing the virus to evade host cell 
immune proteins [17].  
The Gag polyprotein is encoded by gag gene, while the Gag-Pol polyprotein is produced 
as a result of a frame shift event during translation that joins the gag and pol reading frames 
(Figure 1.1b). Together, the intact Gag and Gag-Pol polyproteins play an essential role shuttling 
and packaging viral components, including viral RNA and viral proteins, into the progeny virus. 
Once the progeny virus detaches, both Gag and Gag-Pol polyproteins are processed by PR. Gag 
polyprotein is then cleaved to produce the proteins MA, CA, NC, p6 and two spacer proteins p1 
and p2. Since the Gag and Gag-Pol polyproteins share the same N-terminal sequence, cleavage 
of the Gag-Pol polyprotein also produces MA, CA, and NC. In addition, PR cleavage of the Gag-
Pol polyprotein also produces the transframe protein (TF) and the subunits essential in the 
formation of mature RT, IN, and RT. As a result of PR processing, the virus undergoes 
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morphological changes called maturation, which is marked by the formation of the fullerene 
cone. The detached mature progeny virus can then infect neighboring cells and reiterate through 
the viral lifecycle to produce more progeny viruses [8, 18].  
1.1.1 HIV-1 treatment and drug resistance 
Although new evidence suggests HIV-1 spread to the US in the early 1970, awareness and 
recognition of HIV-1 as a serious health condition only began in 1981 with the first description 
of a previously healthy patient with a rare opportunistic infection.  By the end of 1981, over 200 
similar cases had been reported [8, 19-23]. Due to lack treatment options at this time, patient care 
often focused on the management of opportunistic infections and AIDS related symptoms. In 
1987, HIV-1 specific treatment was revolutionized when the Food and Drug Administration 
(FDA) approved zidovudine (AZT), a nucleoside analog RT inhibitor (NRTI) lacking a 3′ 
hydroxyl that prevents the effective production of proviral DNA by causing early chain 
termination during reverse transcription. By 1996, five other NRTIs were approved including 
didanosine (ddI), zalcitabine (ddC), stavudine (d4T), and lamivudine (3TC) [24]. Initially NRTIs 
were given as mono-drug therapy and dual-drug therapy, which produced positive treatment 
outcomes including the increased life-span of infected individuals. But, these benefits were 
temporary, and treatment with NRTIs led to the rapid development of resistant HIV-1 variants 
[25].  
Subsequent advances in HIV-1 treatment were made with the development of other 
classes of drugs. Protease inhibitors (PI) saquinavir (SQV) and indinavir (IDV) were approved in 
1995 and 1996, respectively, which bind to the active site of PR and act as competitive 
inhibitors.  In 1996 and 1998, the FDA approved nevirapine (NVP) and efavirenz (EFV), 
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respectively, which inhibit RT allosterically by binding to a pocket distinct from the active site. 
Due to their distinct mechanism of action, these inhibitors were named non-nucleoside RT 
inhibitors (NNRTIs).  In the late 1990s, several important studies demonstrated the benefits of 
triple-drug therapy, which typically comprise drugs from three different drug classes, including 
NRTIs, NNRTIs, and PIs [26-29]. This treatment was named Highly Active Antiretroviral 
Therapy (HAART) and became the standard of care by 1998. With proper adherence, this 
treatment regimen has produced declines in the rates of hospitalization, AIDS, and death [3, 30]. 
Currently, 24 inhibitors are approved by the FDA. These include second- and third- generation 
RT and PR inhibitors, including NRTIs, NNRTIs, and PIs. In addition, a fusion inhibitor (FI), an 
entry inhibitor (EI) and integrase inhibitors (INSTs) have also been developed. Many of these 
FDA approved drugs were discovered using high-throughput methods. Of note, the development 
of some of these drugs, in particular the second- and third-generation inhibitors, can be attributed 
to significant advances in structural biology, which facilitated the structure determination of 
many HIV-1 enzymes and led to the success of structure-based drug design [3]. As a result of 
decades worth of research, HIV-1 infection has changed from a life-threatening disease to a 
manageable chronic condition.  
However, even with current treatments, HIV-1 infection can lead to the emergence of 
drug resistant HIV-1 variants [2]. The emergence of drug resistant HIV-1 variants can be 
attributed to the virus’s high genetic variability, which is facilitated by an error prone RT that 
does not correct errors by proofreading. Consequently, RT has an error rate per detectable 
nucleotide of 1/1700, compared to 1/17000 and 1/30000 in avian and myeloblastosis and murine 
leukemia viruses, respectively. In addition, mutational hotspots were found where the error rate 
was higher, a much as 1/70 [31].  As a result, of the high genetic variability and short life cycle 
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(half-life of ~2 days), almost complete replacement of wild-type (wt) virus in plasma by drug-
resistant variants can occur after fourteen days [32, 33]. 
Interestingly, it has been found that a single transmitted/founder virus establishes a 
productive HIV-1 infection. But, over time, the high genetic variability of the viruses leads to the 
production of HIV-1 variants [34, 35]. As a result, within an infected individual there can be a 
heterogeneous mixture of HIV-1 variants that compete for resources necessary for replication. 
The relative population of each HIV-1 variant relies on many factors including its adaptation to 
the host’s intracellular environment. As a result, in the presence of HIV-1 inhibitors, only HIV-1 
variants with reduced susceptibility will persist, shifting the relative population of HIV-1 
variants and eventually leading to therapy failure. Currently, resistance has been documented for 
all antiretroviral drug classes. Therefore new HIV-1 treatments will be needed as the virus 
continues to evolve and acquire drug resistance mutations [2]. 
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Figure 1.2 HIV-1 variants within an infected individual 
a) Although HIV-1 infection begins with a single transmitted/founder virus, overtime a heterogeneous 
mixture of HIV-1 variants can arise within an infected individual, all compete for resources. As a result, 
HIV-1 variants with reduced susceptibility to HIV-1 drugs will persist leading to treatment failure. 
1.1.2 HIV-1 RT 
Since RT is essential for HIV-1 replication, RT continues to be an attractive target for 
therapeutic interventions, [4, 36]. To develop novel inhibitors with more favorable resistance 
profiles, it is important to gain a thorough understanding of RT, its structure, and mechanism of 
inhibitor action. Towards this goal, significant efforts have been made to gain structural insights 
into RT, drug resistant variants of RT, and RT-inhibitor interactions.  
X-ray crystallography has been invaluable to obtain the molecular details of RT. There 
are over 200 of crystal structures of RT currently available [37-57]. A comparison of the 
available X-ray crystal structures shows that mature HIV-1 RT is an asymmetric heterodimer 
composed of two subunits named p66 and p51. The p66 subunit contains two domains, the 
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polymerase and RNase H (RNH) domains. The p66 subunit is further divided into subdomains, 
named fingers, thumb, palm, and connection. The arrangements of the subdomains in the p66 
subunit resemble a right hand. The p51 subunit shares the same N-terminal sequence as the p66 
subunit, but lacks the RNH domain. Consequently, the p51 subunit also contains the fingers, 
thumb, palm and connection subdomains but, given the asymmetry of the mature enzyme, the 
subdomains have different spatial arrangements within the subunit (Figure 1.3).   
 
 
Figure 1.3 General description of RT structure 
Tube representation of apo-RT (PDB: 1DLO [52]), with the fingers, palm, thumb, connection, and RNH 
domains in the p66 subunit colored in blue, red, green, yellow and orange, respectively. The p51 subunit 
is colored grey. 
 
Structures representing several functional states of RT have been reported including: apo-
RT, DNA-RT complex, and dNTP-DNA-RT complex. Analysis of these X-ray structures reveals 
major conformational rearrangements upon substrate binding, resulting from hinge movements 
of the subdomains relative to each other, while the structure of individual subdomains remains 
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almost invariant. The defining feature of most apo-RT X-ray crystal structures is the “closed 
conformation” of the fingers and thumb subdomains in the p66 subunit, where the fingers and 
thumb subdomain appear to clamp down on each other [38].  In contrast, in DNA-RT crystal 
structures the fingers and thumb subdomains in the p66 subunit are in the “open conformation”, 
forming a large cleft to bind dsDNA substrate [39].  The dsDNA stretches from the polymerase 
active site to the RNH active site interacting with the connection subdomains of both the p66 and 
p51 subunits, which is ~60 Å in length.  The binding of dNTP results in the fingers subdomain 
folding down in the presence of dsDNA, closer to the palm subdomain [37-39].  
 X-ray structures of RT in the presence of several inhibitors are also available. A 
comparison of crystal structures of apo-RT and RT in the presence of NNRTIs, shows significant 
structural changes upon NNRTI binding. In the presence of NNRTIs, p66 thumb adopts an “open 
conformation”, where the thumb is 30 Å away from the fingers subdomain. Changes are also 
observed in the NNRTI-binding pocket, located in the p66 subunit, which is lined by aromatic 
(Y181, Y188, F227, W229, and Y232), hydrophobic (P59, L100, V106, V179, L234, and P236), 
and hydrophilic (K101, K103, S105, D132, and E224) residues [52].  Most NNRTIs contain a 
common pharmacophore scaffold, including moieties capable of hydrogen bonding, aromatic 
ring(s) that participate in π-π interactions, and hydrophobic domain able to interact with the 
hydrophobic region of the NNRTI-binding pocket [36, 46, 58, 59]. X-ray crystallography has 
been invaluable for providing details of enzyme-substrate interaction. However, studies by other 
methods are necessary to provide true understanding of the systems under investigation. Here we 
use solution NMR to study RT in solution.   
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1.2 NMR SPECTROSCOPY OF PROTEINS 
1.2.1 A brief history of protein NMR 
The pioneering work of many researchers laid the foundation for modern protein NMR 
spectroscopy, including early studies by Wolfgang Pauli in 1924, who proposed that nuclei 
should posses spin angular momentum [60], and Isidor Isaac Rabi, who demonstrated the nuclear 
resonance effect from metal ions in a vacuum [61]. In 1945 groups led by Felix Bloc and Edward 
Purcell demonstrated resonance effects from solid and liquid samples. Early protein NMR 
studies including the first 1H NMR spectrum of a protein ribonuclease A in 1957 by Martin 
Saunders [62] and a spectral comparison between native and denatured protein by Bovery in 
1959 [63, 64]. 
These early studies were often difficult due low sensitivity and the narrow chemical shift 
dispersion in the proton dimension [65]. Therefore, subsequent advances in instrumentation and 
processing methodologies aided development of NMR studies on biological macromolecules. 
Some of the important developments include the introduction of signal averaging [66, 67] and 
pulsed Fourier transform NMR [68], which reduced acquisition time and quantity of protein time 
required. In addition, significant advances were made in the development of high field magnets, 
and by 1952 spectrometers became commercially available [65]. In 1967, McDonald and Phillips 
reported the first use of a superconducting magnet (220 MHz) to obtain NMR spectra of protein. 
Their work demonstrated that improved spectra could be acquired at higher field strengths [69]. 
This work helped stimulate interest in the development of even more powerful magnets.  
Following this time, there was significant progress brought about by the work of several 
laboratories. In the 1970s Richard Ernst was a key figure in the introduction of two-dimensional 
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(2D) NMR experiments, which provide information on correlations between two nuclei (either 
via J connectivities or cross relaxation pathways), and result in spectra with two frequency 
dimensions [70]. Shortly after, Kurt Wüthrich applied 2D correlation spectroscopy to study 
proteins, and by 1983 his group was routinely using a variety of 1H NMR experiments to obtain 
the resonance assignments of several small proteins [71, 72]. The first solution structure of a 
protein, which was calculated using 2D NOE distance restraints, was published in 1985 Kurt 
Wüthrich [73]. By the second half of the 1980s, 1H NMR became an established tool for the 
structure determination of proteins up to 100 residues [74].  
In the late 1980s, structure calculations of proteins larger than 100 residues were still 
difficult. One challenge for large proteins is the spectral overlap caused by the high number of 
signals, making it difficult to resolve and unambiguously assign individual resonances. To 
address this problem, 3D NMR experiments were introduced [74-81], first with unlabeled 
proteins, and then with 13C and 15N labeled proteins [80, 82]. With these new sets of 
experiments, resonance assignments were considerably easier, allowing the determination of 
larger protein structures. Also in the late 1980s, more robust methods for structure 
determinations were developed by Clore and Gronenborn [75, 78, 79]. With their simulated 
annealing methods, which combine experimentally determined restraints with molecular 
dynamic simulations, NMR structures could be calculated with comparable precision and 
accuracy of 2 Å resolution crystal structures [83]. 
1.2.2 Applications of NMR in the study of protein in solution 
After decades of research, NMR spectroscopy is now considered a key technique for structural 
biology. In fact, the number of protein structures available in the PDB determined using NMR 
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exceeds 10,000 [84-87]. NMR is not limited to the structure determination of proteins. It is also 
considered a powerful and versatile spectroscopic tool for the study protein-ligand interactions, 
dynamics, and protein folding [88-92]. A detailed description of all NMR applications is beyond 
the scope of this thesis. Therefore, I only highlight two topics pertinent to my work: protein 
structure determination and protein-ligand interactions. 
1.2.2.1 Protein structure determination 
Current NMR methods for protein structure determination use molecular dynamics simulations 
to generate an ensemble of models consistent with the experimental data (e.g, dihedral angles 
constraints based on coupling constants, dipolar coupling constraints, and intra- and inter-proton 
distance constraints) and known features of proteins (e.g. bond lengths, and van der Waals radii) 
[78, 93, 94]. Briefly, strategies to obtain some of the experimental data are discussed below.  
Since protein structure determination relies primarily on the ability to obtain interproton 
distance constraints, near complete resonance assignments are essential. Assignment strategies 
largely depend on isotopic labeling of the protein [95]. For 15N, 13C labeled proteins, strategies 
favor the use of 3D experiments (to help reduce spectral overlap) based on through- bond 
connectives (to help avoid ambiguities in the assignment processes) [95]. For backbone 
assignments, 3D CBCANH and CBCA(CO)NH experiments correlate the N(i)/HN(i) chemical 
shifts of residue (i) with the Cα and Cβ chemical shifts of residues (i) + (i-1), and of residue (i-1), 
respectively [96]. The chemical shifts, together with primary sequence of the protein, can then be 
used to assign resonances to individual nuclei. For side chain assignments, 3D HBHA(CO)NH, 
H(CCO)NH, and CC(CO)NH are useful. These experiments correlate the N(i)/HN(i) chemical 
shifts of residue (i) to chemical shifts Hα/Hβ,Haliphatic, and Caliphatic of residue (i-1), respectively 
[97]. In addition, 3D HCCH TOCSY experiments, which provide chemical shifts for Caliphatic and 
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Haliphatic on the same residue, can be used to complete or confirm H and C side chain assignments 
[98].   
 Once the backbone and side chain resonances have been assigned, interproton constraints 
can then be obtained using nuclear Overhauser enhancement spectroscopy (NOESY) 
experiments. Nuclear Overhauser Effect (NOE) result from a distance dependent cross relaxation 
due to dipole-dipole interactions between NMR observable nuclei. For 1H-1H NOESY 
experiments, the spectra have two general features: peaks along the diagonal for protons that do 
not exchange magnetization components and cross-peaks between the coupled protons [99]. 
These data are qualitatively used to produce NOE interproton distance constraints, which are 
classified into three distance ranges, 1.8-2.5, 1.8-3.5 and 3-5 Å, corresponding to strong, medium 
and weak NOEs [76].   
Dihedral angle constraints can also be useful. Backbone dihedral angles, can vary from -
180˚ to 180 ˚, but due to steric restrictions, they do not adopt all possible values. The allowed 
ranges of ϕ and ψ angles for different secondary structural elements can be visualized using 
Ramachandran plots [100]. Since dihedral angles provide important information on the 
secondary structure of a protein, these values are important for structure generation, and/or to 
improve structure quality [101]. Several methods to derive torsion angle constraints have been 
proposed, including three-bond J couplings [76], Cα/Cβ,chemical shifts [101], and a database 
method such as, TALOS+ that predicts torsion angles based on chemical shifts and high-
resolution X-ray structures [102]. These strategies all depend on the fact that chemical shifts are 
highly sensitive to local structure. 
Dipolar couplings are distance and angle dependent through-space interactions between 
two NMR observable nuclei [103]. In solution, the orientation dependent magnetic interactions 
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average out to zero due to isotropic Brownian motion. In contrast, in weakly aligning media, 
such as media containing filamentous bacteriophage, anisotropically compressed acrylamide 
gels, or detergent phases, a non-zero value for the orientation dependent residual dipolar 
coupling (RDC) can be measured [104, 105]. Since the distance between two nuclei connected 
by one bond is essentially fixed, for example between 15N and 13C atoms and their attached 
hydrogens, RDCs provide information about the orientation of the internuclear vectors relative to 
the protein’s magnetic susceptibility axis. RDCs work well in the refinement stage of the 
structure calculation and increases the precision and accuracy of the structures [103]. 
Paramagnetic relaxation enhancement (PRE) and pseudocontact shifts (PCS) are useful to 
obtain long-range distance constraints [106-109]. The PRE effect arises from interactions 
between the unpaired electron of a paramagnetic spin label and NMR observable nuclei. Due to 
the large magnetic moment of the paramagnetic center, there is distance dependent (r-6) increase 
in the relaxation rate of NMR observable nuclei within 15-35 Å. Distance-dependent line 
broadening effects can then be used to generate long-distance constraints for structure 
calculations [108]. These experiments work well for proteins with an intrinsic paramagnetic 
group, or those problems that contain a site specifically conjugated paramagnetic moiety [89].   
PCS can also provide long-range information for structure calculations. PCS are observed 
for paramagnetic ions with an anisotropic magnetic susceptibility tensor 𝜒𝜒, such as Fe3+, and lanthanide ions. The large magnetic susceptibility tensor also produces a weak alignment of the protein in the field, resulting in RDCs with long-range information. In contrast to PREs, PCS are governed by a distance dependence of (r -3), to measure longer distances up to  
~ 40 Å [89, 109, 110].  
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1.2.2.2 studies of large proteins 
In 15N-1H or 13C-1H correlation experiments the scalar spin-spin coupling splits the signal from 
each nucleus into two components. As a consequence, in two-dimensional (2D) heteronuclear 
correlation experiments, a four-line multiplet is observed. Current NMR techniques often 
collapse the multiplet by a technique called decoupling, resulting in a single, centrally located, 
averaged signal. For small proteins at high magnetic fields, decoupling of the four-line multiplet 
results in a simplified spectrum with improved sensitivity.  For large proteins, decoupling results 
in a spectrum with reduced sensitivity, due to the fast transverse relaxation which occurs with a 
time constant T2. As a result, assignments strategies for protein above 30 kDa  are more difficult 
[111]. 
 Major sources of transverse relaxation in a heteronuclear spin system include both the 
dipole-dipole relaxation (DD) and chemical-shift anisotropy (CSA) [112]. The rate of dipole-
dipole interactions is field-independent while the chemical shift anisotropy is field-dependent.  
At high magnetic fields, the CSA can significantly contribute to the transverse relaxation of large 
proteins [113]. As a result, the components of the four-line multiplet have different linewidths, 
and decoupling results in a reduced average signal. The linewidths of the four-line multiplet are 
field-dependent, such that at around 900-1000 MHz (for the 15N-1H moiety) the difference in 
linewidth of the four-line multiplet is the greatest. Around this magnetic field strength, there is a 
significant reduction of the transverse relaxation of one of the four-line multiplet, producing a 
signal of narrow linewidth.  In a transverse relaxation-optimized spectroscopy (TROSY) 
experiment, there is no decoupling and the narrow line of the multiplet is selected.  
TROSY experiments can be optimized using partially deuterated proteins in H2O, where 
the solvent accessible amide deuterons are exchanged for NMR-observable protons. Since the 
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relaxation of the of the narrow component of the multiplet is mostly affected by DD interactions 
with remote hydrogen atoms outside of the 15N-1H moiety [114] the replacement of protons with 
deuterons reduces proton-proton DD and scalar couplings, resulting in narrower linewidths 
[115].  
Although experiments using partially deuterated proteins have shown promise, 
deuteration removes most of the side chain protons essential for NOE analysis. To address this 
challenge, methods have been developed to selectively protonate methyl groups in highly 
deuterated proteins. With the augmented NOE data set, these methods can be used to study 
proteins  up to 100 kDa [116].  
Another approach to study large protein is to use the “divide and conquer” approach, 
which divides the protein into smaller, more tractable pieces [117]. For these studies, parts a 
large multi-domain proteins are isotopically labeled and purified separately. Then, if the spectra 
of these domains are sufficiently similar to the spectra of full-length protein, spectra of the 
smaller pieces are assigned using traditional 15N, 13C correlation experiments.  These 
assignments can then be transferred to the full-length protein. A similar approach has been 
utilized to study multi-oligomeric proteins with a high degree of symmetry [118]. For these 
proteins, the total NMR signals of the full-complex is usually reduced in comparison to a protein 
of similar size and less symmetry (assuming that each nucleus in the monomeric subunit is 
usually in the same chemical environment). Mutations that disrupt the oligomeric surface must 
be found, which is often challenging and may require significant effort. Once the monomeric 
subunit is isolated, spectra for the monomeric subunit are assigned using conventional labeling 
and NMR techniques, and assignments are then transferred to the multi-oligomeric protein.  
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1.2.2.3 Isotopic labeling to study protein-ligand interactions 
Solution NMR can be an exceptionally sensitive tool to study protein-ligand interactions. These 
experiments can be divided into two classes. Protein-observe and ligand-observe NMR. 
Currently, several informative reviews covering these topics are available [88, 89]. Briefly, in the 
section below, I include a description of protein-observe experiments for 15N-, 13C- and 19F- 
labeled proteins. 
In protein-observe NMR experiments of protein-ligand interactions, the 
intensity/chemical shift changes are monitored by titrating ligand into a solution containing 
isotopically labeled proteins.  Chemical shift changes upon ligand binding can result from direct 
interactions with the ligand, or from long range conformational rearrangements. Therefore, to 
help reduce ambiguities between local and long range conformational changes, several chemical 
shift changes are measured and mapped onto the 3D protein structure. Experiments for 15N 
labeled proteins use 2D 1H-15N HSQC, or TROSY based experiments for larger proteins[89]. 
Preparation of 15N-labeled protein, expressed using bacterial systems, is now considered 
relatively straightforward and only requires growth in minimal media supplemented with 15N-
labeled ammonium chloride.  
Another approach is to use 13C-methyl labeled proteins, which contain 13C probes in the 
side chain of the protein, such as alanine, valine, isoleucine, leucine and methionine. For 13C-
methyl labeled proteins, 2D 1H-13C HMQC experiments are typically used. These experiments 
have some advantages in comparison to 1H-15N HSQC experiments. Specifically, methyl groups 
have three protons with a three-fold degeneracy and give rise to stronger signals. They also tend 
to resonate in a sparsely populated region of the 1H-13C correlation spectrum, reducing spectral 
overlap [119]. Several suitable labeling schemes for the six canonical methyl-containing amino 
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acids, including alanine, isoleucine, leucine, methionine, and threonine, have been developed 
[120]. These labeling schemes often exploit metabolic pathways, metabolic precursors, and the 
amino acid’s propensity for isotopic scrambling at other sites in the protein. For leucine and 
valine, which share the same metabolic pathway, labeling techniques often result in the 
incorporation of isotopes into both amino acids. Successful labeling schemes have been carried 
out by using metabolic precursors common to both amino acids, such as α-ketoisovalerate. 
Isoleucine, can also be labeled using α-ketobutyrate, one of its metabolic precursor [121-124]. 
For alanine and methionine, residue specific labeling can be achieved by supplementing minimal 
expression medium with the appropriate isotopically labeled amino acid. This labeling strategy 
often results in a considerable amount of isotopic scrambling when labeling alanine residues, 
since alanine is synthesized from the reversible transamination of pyruvate. Therefore, to reduce 
isotopic scrambling, the expression media can be supplemented with deuterated amino acids 
and/or metabolic precursors of amino acid in the relevant metabolic pathways that alanine might 
contribute to, such as α-ketoisovalerate [117, 125-128]. Unlike alanine, methionine at the end of 
its metabolic pathway. Therefore, directly supplementing the expression media with 13C-methyl 
methionine has been found to result in low or undetectable amounts of isotopic scrambling [117]. 
Although classical 1H, 13C, and 15N spectroscopic approaches have been used extensively 
to study proteins in solution, 19F NMR is gaining increasing popularity. As discussed previously 
[129, 130] the 100% naturally abundant 19F atom displays several properties that render it ideal 
for NMR exploitation: It possesses a spin 1/2 nucleus and a high gyromagnetic ratio that results 
in excellent sensitivity (83% of 1H). In addition, the shielding of the 19F nucleus is dominated by 
a large paramagnetic term and, as a result, fluorine chemical shifts are exquisitely sensitive to 
changes in local environment (the chemical shift range is ~100-fold larger than that of 1H). 
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Another great advantage of using 19F as an NMR probe is its absence from virtually all naturally 
occurring biomolecules, small and large. For this reason, studies of fluorinated biopolymers can 
be carried out in any routinely used buffer system or environment without suffering from 
interference by background signals. Thus, no special precautions are needed to remove buffer 
and additive signal intensity from the spectra. The van der Waals radius of the 19F atom (1.47 Å) 
lies between those of hydrogen (1.2 Å) and oxygen (1.52 Å), and strategic substitution of 19F 
atoms for hydrogens, hydroxyl groups, or carbonyl oxygens in biological molecules is 
considered weakly perturbing and often has little effect on a protein’s biological activity [129-
132].  
For 40 years now, the 19F atom has been exploited in biological NMR [133, 134], and 
several reviews have covered the field over the last four decades [129-131, 135, 136]. Indeed, the 
19F atom has been used as a molecular probe to gain insight into protein and peptide structure 
[129, 130, 137], protein-ligand interactions [129-132, 138, 139], protein unfolding [133, 134, 
140, 141], protein aggregation [129-131, 135, 136, 142, 143], and protein dynamics [144],  
clearly demonstrating the power and versatility of the fluorine probe for NMR.  
Several methods to prepare 19F-modified proteins have been described [129, 131, 145-
148]. These methods fall into three main categories: (i) post-translational covalent attachment of 
19F-containing moieties to the protein, (ii) biosynthetic amino acid type-specific incorporation of 
19F-modified amino acids, and (iii) site-specific incorporation of 19F-modified amino acids using 
recombinantly expressed orthogonal amber tRNA/tRNA synthetase pairs.  
In brief, post-translational covalent modification introduces 19F atoms into the protein of 
interest by conjugating a 19F-containing moiety to a reactive group, such as an -SH group on a 
solvent accessible cysteine [137, 138]. One advantage of this technique is the ability to 
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incorporate the label into proteins for which biosynthetic labeling is cost-prohibitive, such as 
proteins expressed in mammalian cells.  For residue-specific incorporation of 19F-modified 
amino acids into proteins, expression is carried out in defined growth media supplemented with 
the 19F-modified amino acid. This method relies on the endogenous aminoacyl-tRNA synthetases 
to charge the 19F-modified amino acid onto their cognate tRNAs. As a result, all codons 
recognized by the amino acid-specific tRNA will carry the 19F-modified amino acid, and global 
incorporation of the 19F-modified amino acid into all proteins will occur. To maximize the 
efficiency of 19F-labeled amino acid incorporation, auxotrophic bacterial strains that cannot 
synthesize the amino acid that is to be replaced are sometimes used, but frequently are not 
necessary [149, 150]. Still, for some amino acids, >90% labeling can be achieved if conditions 
are worked out carefully. Potentially the most powerful and versatile method to introduce 19F 
atoms into proteins is site-specific incorporation of 19F-modified amino acids using a 
recombinantly introduced orthogonal amber tRNA/tRNA synthetase pair. This method is based 
on an extension of the genetic code to beyond the natural 20 amino acids, first described by 
Noren and colleagues in 1989 [151]. It uses nonsense stop codons and nonsense suppressor 
tRNAs to overturn termination of protein biosynthesis and requires engineered aminoacyl-tRNA 
synthetases that specifically acylate the suppressor-tRNAs with the non-natural 19F-modified 
amino acid in vivo, without interfering with other tRNA/synthetase pairs. Application of this 
approach entails the introduction of the amber nonsense codon (TAG) at any desired location in 
the protein coding sequence, such that it replaces the natural amino acid codon in that location, in 
conjunction with introduction of a tailored orthogonal amber tRNA/tRNA synthetase pair. More 
specifically, a vector containing the protein amber-mutant gene is co-introduced into an E.coli 
host strain along with a vector encoding an in vitro evolved orthogonal amber tRNA/tRNA 
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synthetase pair that recognizes the 19F-modified amino acid. Expression is then carried out in 
growth media supplemented with the 19F-modified amino acid. One drawback of this 
methodology is the fact that the orthogonal amber tRNA/tRNA synthetase pair does not 
incorporate the 19F-modified amino acid with 100% efficiency at the amber codon and that 
translation termination occurs to varying degrees. As a result, two protein products are invariably 
generated, an undesired unlabeled truncated protein, and a 100% labeled full-length protein. 
These two proteins can be separated during purification if a C-terminal affinity tag is used. All 
three methods are schematically illustrated in Figure 1.4. The fluorine labeling section was 
adapted from [153]. 
 
 
 
Figure 1.4 The three main methods to prepare 19F-modified proteins are shown.  
a) Posttranslational covalent conjugation of 19F-containing moieties to the protein. b) Biosynthetic amino 
acid type-specific incorporation of 19F-modified amino acids. c) Site-specific incorporation of 19F-
modified amino acids using recombinantly expressed orthogonal amber tRNA/tRNA synthetase pairs.  
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2.0  SUMMARY OF PROJECTS  
Solution NMR is powerful for de novo structure determination and to obtain site-specific 
informational on large proteins. Given RT’s size, conventional NMR experiments that use 
protein uniformly labeled with 13C and 15N are challenging. Therefore, we use several different 
strategies to study RT in solution.  In particular, we used the “divide and conquer” approach to 
study the p66 immature precursor of RT (Chapter 5.0). We also use the “divide and conquer” 
approach combined with traditional NMR methods for structure determination of the isolated 
thumb subdomain of RT (Chapter 6.0). Furthermore, we selectively introduced and 
trifluoromethyl phenylalanine (tfmF) to study RT-inhibitor interactions (Chapter 7.0).  
Together, our studies provide important novel information regarding RT maturation, the 
structure of the HIV-1 thumb subdomain, and RT-inhibitor interactions.  
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3.0  PROTEIN EXPRESSION AND PURIFICATION. 
All the studies in this thesis use similar protocols to produce and purify RT proteins. Therefore, 
in an effort to reduce redundancy, all these procedures have been grouped into one section. This 
chapter includes the construction of the protein coding genes section 3.1, protocols used for 
producing unlabeled and isotopically labeled proteins section 3.2, and purification protocols for 
RT proteins, subunits and (sub)domains section 3.3.  
3.1 CLONING 
The coding sequence for the RT p66 subunit was amplified from the p6HRT-PROT vector, 
kindly provided by Dr. Sluis-Cremer, using 5’-acc gca cat atg ccc att agc cct att gag act gta-3’ 
and 5’-gca gat ctc gag tag tat ttt cct gat tcc agc act gac-3’ as forward and backward primers, 
respectively. The amplified product was inserted into the pET21a(+) vector (Invitrogen, 
Carlsbad, CA), which encodes a six histidine tag at the C-terminus of the protein construct. After 
initial expression and purification trials, a codon-optimized C280S/C38V double cysteine 
version was created for increased protein expression in E. coli (DNA 2.0 gene synthesis, Menlo 
Park, CA). The coding sequence for the p51 subunit with an N-terminal Strep-tag was created by 
amplification of the appropriate region (coding for residues 1-440) of the p66 RT codon 
optimized sequence, using 5’-cc gca tcc atg gat tgg agt cac ccg cag ttc gag aaa cca atc agc cca atc 
 25 
gaa acg gtc cc -3’ and 5’-ccg cat ctc gag tta gaa cgt ttc cgc gcc aac aat cgg ttc ttt ctc c-3’ as 
forward and reverse primers, respectively, and the amplified product was then inserted into a 
pET28a+ vector (Invitrogen). Constructs coding for residues 1-216 (Finger-Palm domain), 237-
318 (Thumb domain) and 427-556 (RNH domain) were amplified from the p66 sequence using 
5’-gca gct cat atg cca atc agc cca atc gaa acg gtc cc-3’ and 5’-gca gat ctc gag ggt cgt cag acc cca 
acg cag cag atg c-3’ as forward and backward primers, respectively, for the finger-palm domain, 
5’-cgt acg cat atg gat aaa tgg aca gta cag cct ata gtg ctg cc-3’ and 5’-cgt acg ctc gag ata cac tcc 
atg tac tgg ttc ttt tag aat ctc-3’ as forward and backward primers, respectively, for the thumb 
domain, and 5’-gca gat cat atg tat caa ctg gag aaa gaa ccg att gtt ggc-3’ and 5’-gca gat ctc gag 
cag gat ttt gcg aat acc tgc gct cac c-3’ as the forward and backward primers, respectively, for the 
RNH domain. See figure 3, for visual a representation of the amplified p66 coding regions used 
to produce RT subunits and (sub)domains.  
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Figure 3.1 General description of RT structure and schematic representations of the p66 coding regions 
amplified to produce RT subunits and (sub)domains. 
(a) Tube representation of HIV-1 RT.  b) Schematic representation of the p66 gene, labeled to indicate the 
coding regions for RT proteins. The fingers-palm, thumb, connection, and RNH (sub) domains in the p66 
and p51 subunits colored in magenta, green, yellow and orange, respectively 
 
For singly 4-trifluoromethyl phenylalanine (tfmF)-labeled proteins, the vectors encoding 
p66-127tfmF, p66-146tfmF, and p66-181tfmF proteins, were generated by replacing codons for 
tyrosines at positions 127, 146, or 181 with amber codons, using the appropriate TAG 
oligonucleotides as primers, and the p66 encoding vector as a template. The vectors encoding 
mutant p66-181tfmF, p66-146tfmF and p51 proteins (p66-181tfmF-K103N, p66-181tfmF-
V108I, p66-146tfmF-K103N, p66-146tfmF-V108I, and the p51-V108I, p51-E138K, p51-
K103N) were generated using the appropriate oligonucleotides as primers, and the p66-181tfmF, 
p66-146tfmF, and p51 encoding vectors as templates, respectively. All the p66, thumb, RNH, 
and finger-palm constructs contain a hexa-histidine tag at the C-terminus, and all the p51 
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constructs contain a Strep-tag at the N-terminus. The DNA sequences of all constructs were 
verified by DNA sequencing (Genewiz, South Plainfield, NJ). 
3.2 PROTEIN PRODUCTION 
Unlabeled proteins (p51, p51-V108I, p51-K103N, p51-E138K) were produced in E. coli BL21 
(DE3) gold cells (Agilent Technologies, Santa Clara, CA), using 0.5 mM IPTG for induction 
over 16 hours at 27oC or by growing cells for 24 h 27oC using auto-induction medium [152, 
153].  
Uniform 15N-labeling of the isolated Finger-Palm, Thumb, and RNH domains was 
achieved using modified minimal medium containing 15NH4Cl as the nitrogen source.  Uniform 
15N- and 13C-labeling of the Thumb and RNH domains, was carried out, using 15NH4Cl and 13C6-
glucose as sole nitrogen and carbon sources, respectively. Uniform 15N- and 2H- labeling of the 
p66 and the p51 protein was achieved in modified minimum medium containing 2H2O and 
15NH4Cl.  
The tfmF labeled p66 proteins (p66-127tfmF, p66-146tfmF, p66-181tfmF, p66-181tfmF-
V108I, and p66-181tfmF-K103N) were produced using a protocol developed by the Mehl 
laboratory [147, 153]. Briefly, competent E.coli BL21 ai cells (Invitrogen) were co-transformed 
with the vector encoding the TAG containing constructs (above), and the pDule2 RS vector 
encoding the orthogonal amber tRNA/tRNA synthetase pair. Several transformants were 
screened for expression. All tfmF containing p66 proteins were produced at 27°C by growing 
cells for 24 h using auto-induction medium, containing tfmF at a final concentration of 1 mM.  
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3.3 PROTEIN PURIFICATION 
Cells were harvested by centrifugation at 5887 g, re-suspended in lysis buffer containing 25 mM 
sodium phosphate (pH 7.5), 25 mM imidazole and 500 mM NaCl, and lysed using a 
microfluidizer. Cell debris was removed by centrifugation at 34530 g. Purification of RT 
proteins generally involve the use of a combination of four columns: 5 mL HisTrap column, 
StrepTrap column, 5 mL HiTrap SP column and HiLoad 26/60 Superdex 200 column (GE 
Healthcare). For purification steps using the HisTrap column, the column was equilibrated with 
lysis buffer and eluted with a linear gradient of 0.025-0.5 M imidazole (except for p51 proteins). 
For purification steps using the StrepTrap column, the column equilibrated in 25 mM sodium 
phosphate, 6 mM KCl, 280 mM NaCl (pH 7.5) and proteins were eluted using the same buffer 
listed above supplemented with D-desthiobiotin to a final concentration of 3 mM (Sigma 
Aldrich, St. Louis, MO). For purification steps using the HiTrap SP column, the column was 
equilibrated with 25 mM sodium phosphate (pH 6.5), and eluted using a linear gradient of 0-0.5 
M NaCl. For purification steps using the HiLoad 26/60 Superdex 200 gel filtration column, 
phosphate-buffered saline was used. 
The thumb, RNH and finger-palm (sub)domains and the p66 proteins, which contain a C-
terminal His-tag, were purified over a 5 mL HisTrap column, followed by 5 mL HiTrap SP 
column. 
For the p51 proteins, which contained an N-terminal Strep-tag, the supernatant after cell 
lysis and centrifugation was loaded onto a 5 mL HisTrap column. The flow through was 
collected and further purified over a 5 mL StrepTrap column, followed by a 5 mL HiTrap SP 
column. 
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For RT proteins, equivalent amounts of cell pellets, containing the expressed p66 and p51 
proteins, were mixed, and lysed using a microfluidizer. After centrifugation, the supernant was 
applied onto a 5 mL HisTrap column. The elution with a linear gradient of 0.025-0.5 M 
imidazole was essential to separate fractions containing p66/p51 heterodimeric RT proteins from 
p51 monomer, and p66 proteins. RT-containing fractions further purified over 5 mL StrepTrap 
column (GE healthcare), a step essential for the removal of p66 homodimer.  
The final purification step for all protein samples included the use a HiLoad 26/60 
Superdex 200 column (GE Healthcare). Protein fractions were pooled and concentrated in an 
Amicon Ultra concentrator (EMD Millipore, Billerica, MA) to ~10 µM. Glycerol (50% v/v 
glycerol) was added and samples were stored at -20°C for future use. A list of proteins used in 
the following chapters is provided in Table 3.1.  
 
Table 3.1 RT proteins 
 
Proteins Subunits Described in Chapter 
15N thumb subdomain 
15N finger-palm subdomain 
15N RNH 
15N p51  
2H,15N p66  
 
13C, 15N thumb subdomain 
 
RT127tmfF 
thumb subdomain 
finger-palm subdomain 
RNH domain 
p51 
p66 
 
thumb subdomain 
 
p51/p66-127tfmF 
4 
4 
4 
4 
4 
 
4,5 
 
6 
RT146tfmF p51/p66-146tfmF 6 
RT181tfmF p51/p66-181tfmF 6 
RT181tfmF-V108I p51-V108I/p66-181tfmF-V108I 6 
RT181tfmF-K103N p51-K103N/p66-181tfmF-K103N 6 
RT181tfmF-E138K(p51) p51-E138K/p66-181tfmF 6 
RT146tfmF-V108I p51-V108I/p66-146tfmF-V108I 6 
RT146tfmF-K103N p51-K103N/p66-146tfmF-K103N 6 
 30 
4.0  THE P66 PRECURSOR OF HIV-1 RT 
In contrast to the wealth of structural data available for the mature p66/p51 heterodimeric human 
immunodeficiency virus type 1 reverse transcriptase (RT), the structure of the homodimeric p66 
precursor remains unknown. In all X-ray structures of mature RT, free or complexed, the 
processing site in the p66 subunit, for generating the p51 subunit, is sequestered into a β-strand 
within the folded ribonuclease H (RNH) domain and is not readily accessible to proteolysis, 
rendering it difficult to propose a simple and straightforward mechanism of the maturation step. 
Here, we investigated, by solution NMR, the conformation of the RT p66 homodimer. Our data 
demonstrate that the RNH and Thumb domains in the p66 homodimer are folded and possess 
conformations very similar to those in mature RT. This finding suggests that maturation models 
which invoke a complete or predominantly unfolded RNH domain are unlikely. The present 
study lays the foundation for further in-depth mechanistic investigations at the atomic level. The 
results presented in this chapter have been adapted from: Sharaf NG, Poliner E, Slack RL, 
Christen, MT, Byeon, I-JL, Parniak, MA, Gronenborn, AM, Ishima, R (2014) The p66 immature 
precursor of HIV-1 reverse transcriptase. Proteins 82:2343–2352. Cpyright (2014) Wiley 
Periodical, Inc 
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4.1 INTRODUCTION 
RT plays a central role in the replication of all retroviruses and related retrotransposons. In the 
HIV-1 life cycle, RT is expressed as part of the Gag-Pol polypeptide, which is processed by 
retroviral protease into several proteins [154-158]. The mature RT enzyme is a heterodimer, 
composed of two subunits, p66 and p51 (Figure 4.1a) [159-162]. The RT p51 subunit is 
generated by removal of the C-terminal RNH domain from p66 by PR [163-167]. In vivo 
processing of the Gag-Pol polyprotein is complex, and the detailed mechanism of RT maturation 
into the heterodimer is still unclear. Based on data obtained from model systems, cleavage at the 
p51-RNH processing site is assumed to occur in a p66 homodimer [36, 164, 168]. However, in 
all known RT X-ray structures, as well as those of the isolated RNH domain, the p51-RNH 
cleavage site is located within the folded RNH domain, sequestered into the center of a β-sheet, 
and thus seemingly inaccessible to the protease (Figure 4.1b) [36, 39, 169-171]. No significant 
motions were observed at the p51-RNH processing site in the isolated RNH domain [172, 173], 
which may have suggested partial accessibility of the site. In addition, the lack of structural 
information on the “immature” p66 RT precursor renders any mechanistic explanation(s) 
tentative. We, therefore, embarked on studies aimed at providing the foundation for structurally 
elucidating RT processing. 
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Figure 4.1 Ribbon representation of the structures RT and RNH domain  
a) p66/p51 RT heterodimer and b) the RNH domain, indicating the p51-RNH processing site (arrow), and 
c) amino acid sequence of p66. In a)-c), the Thumb and RNH domains in the p66 subunit are show 
 
To evaluate protein conformation in solution, Nuclear Magnetic Resonance (NMR) 
spectroscopy provides powerful approaches [85], since it permits the investigation of 
conformational equilibria and protein dynamics at the amino acid residue level [174-176]. 
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However, NMR studies of HIV RT are challenging, given the protein’s large molecular mass 
(117 kDa); to date, NMR of RT has been mostly limited to observing methyl groups of side 
chains, such as in methionine or isoleucine [177-179]. Although methyl resonances are valuable 
probes for obtaining general qualitative information about a protein’s conformation in solution 
[124, 180], they report only on a limited number of positions and, therefore, cannot inform on the 
secondary and tertiary structural details that are mirrored by a protein’s backbone chemical shifts 
[181]. 
Here, we present an investigation of the p66 homodimeric RT. The p66 dimer possesses 
enzymatic activity [182, 183] and is widely considered to function as the RT precursor [36, 164, 
168, 184]. We took advantage of the extreme sensitivity of backbone amide resonance 
frequencies to assess conformational similarities between different protein constructs. In the 1H-
15N heteronuclear single-quantum coherence (HSQC) spectrum of the p66 homodimer, over 240 
resonances were observed. Comparison of the p66 spectrum with the spectra of the isolated 
domains revealed that greater than 60 % of the isolated Thumb domain and more than 40 % of 
the isolated RNH domain resonances, respectively, are in very similar positions. In contrast, only 
18 % of the Finger-Palm domain resonances match those of the p66 homodimer. This establishes 
that both the Thumb and RNH domains are stably folded in the immature p66 homodimeric RT 
and exhibit essentially the same structures as in the isolated domains. With these findings in 
mind, the question arises how HIV-1 protease gains access to the p51-RNH processing site in the 
p66 homodimer. Our data suggests maturation models that invoke a complete unfolded or 
predominantly unfolded RNH domain [169, 170] are unlikely, and implies that p51-RNH 
processing may involve selection of a minor conformation or a protease-binding induced 
structure, which is cleaved during maturation.   
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4.2 EXPERIMENTAL PROCEDURES 
4.2.1 NMR experiments 
Samples were buffer-exchanged into NMR buffer (25 mM sodium phosphate, pH 6.8, 100 mM 
NaCl) in an Amicon Ultra concentrator (EMD Millipore). In the final exchange step, the sample 
was concentrated to 350 µL and supplemented with 10% (v/v) D2O. Final protein concentrations 
for NMR experiments were ~200 μM (in monomer). All NMR spectra were recorded at 303 K 
on Bruker 600 and 900 MHz AVANCE spectrometers, equipped with 5-mm triple-resonance, z-
axis gradient cryoprobes.  For p66 and p51 proteins, a TROSY version the 1H-15N HSQC NMR 
experiments was used [114, 185]. For backbone assignments of the thumb and RNH domains 3D 
CBCAONH, HNCACB, and 1H-15N NOESY-HSQC [96] spectra were recorded. All data were 
processed with NMRPipe and analyzed with CCPN analysis [186, 187]. Chemical shifts of 
amide resonances, as defined by Equation 1, were deemed identical if the picked peaks in two 
spectra resided within ± 0.03 ppm.,   
    (1)
 
Here, δ indicates chemical shift in ppm units, and γΝ and γΗ indicate gyromagnetic ratios 
of N and H resonances, respectively. Secondary structure elements were delineated using CSI 
and TALOS+ [102, 188]. Chemical shifts for the Thumb domain spectrum were estimated using 
the coordinates from the crystal structure for residues 237 to 318 of p66 in RT p66/p51 (PDB ID: 
1DLO), with the program Sparta [189].  
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4.2.2 Multi-angle Light Scattering 
Size-exclusion chromatography/multi-angle light scattering (SEC-MALS) data were obtained at 
room temperature using an analytical Superdex 200 (10 × 300 mm, GE Healthcare) column with 
in-line multi-angle light scattering, refractive index (Wyatt Technology, Inc., Santa Barbara, CA) 
and UV (Agilent Technologies) detectors. 100 µL of a protein solution (10.9 - 59.9 μM for p66 
and 19.3 - 58.6 μM for p51) was loaded onto the column, pre-equilibrated and eluted with NMR 
buffer at a flow rate of 0.5 mL/min. The molecular masses of the eluted protein species were 
determined using the ASTRA V.5.3.4 program (Wyatt Technologies). The dimer association 
constant for p66/p66 was extracted from peak intensities at the monomer and dimer molecular 
masses.  
4.3 RESULTS 
4.3.1 Amide backbone resonances of homodimeric p66 
To obtain insight into the conformation of the immature p66 homodimeric RT in solution, 1H-
15N TROSY HSQC spectra of perdeuterated p66 were recorded (Figure 4.2a). Excluding 
resonances that likely arise from amino acid side chains, at least 247 resonances were resolved. 
Although this number is fewer than half of all possible amide resonances (~600), it is still 
remarkable that such a large number is observed, given the large molecular mass of the p66 
homodimer and concomitant line broadening in TROSY HSQC spectra [180, 190]. Note that the 
p66 sample is predominantly a homodimer (>80 %) at the concentration used (~200 μM), based 
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on multi-angle light scattering (MALS) analysis (Figure 4.3a) and a previously reported 
dissociation constant, KD, of 4 μM [163, 165]. 
 
Figure 4.2 1H-15N HSQC spectra   
a) p66 (dark blue), b) p51 (cyan), c) palm-finger (purple), d) thumb (green), and e) RNH (orange). In b)-
e), individual isolated domain spectra are superimposed on the p66 spectrum (dark blue). The insets 
depict expanded regions of the spectra as indicated in panel a). 
 
For comparison, a 1H-15N TROSY HSQC spectrum was also recorded for the p51 sample 
(Figure 4.2b), which contained less than 60 % dimer, based on MALS analysis (Figure 4.3) and 
a reported KD of 230 μM [163, 165]. Given that both our p66 and p51 NMR samples contain 
monomeric and dimeric protein, but give rise to only one set of resonances, the monomer and 
dimer forms are likely in fast exchange on the chemical shift scale. For p51, with a KD >>1 μM 
and an estimated on-rate >106 s-1/M, [191, 192] this is not surprising. For p66, with a KD ~4 μM, 
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the observed chemical shift positions are most likely those of the major dimer species (>80 %), 
irrespective of the exchange régime.  
 
 
Figure 4.3 Multi-angle light scattering (MALS) elution profiles and a portion of the RNH backbone structure 
with a subset of hydrogen bonds highlighted (dashed lines). 
 a) the p66 and b) the p51 protein samples. Experiments were repeated at different protein concentrations 
from 10.9 μM to 59.9 μM and 19.3 μM to 58.6 μM, for p66 and p51 samples, respectively. Assuming that 
the samples are diluted approximately 10-fold on the gel-filtration column, homodimer dissociation 
constants for p66 and p51, calculated from the observed MALS results, are 4.3 ± 0.7 μM and 318 ± 116 
μM, respectively, which are in excellent agreement with the published homodimer dissociation constants 
of ~4 μM and ~230 μM for p66 and p51, respectively. c) We expect that at least these hydrogen bonds 
exist in the p66 homodimer because there are amide cross peaks in the 1H-15N TROSY spectrum of the 
p66 homodimer at positions similar to those of the isolated RNH fragment (<27 Hz). NMR cross peaks 
that are located in overlapped regions could not be evaluated here. The NMR structure of the isolated 
RNH fragment (PDB = 1O1W [193]) was used to generate the graphics. 
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Despite the different proportion of dimerization in the p66 and p51 samples, a significant 
number of amide resonances exhibit the same resonance frequencies in the p51 and p66 NMR 
spectra; this is easily seen upon superposition of the spectra (Figure 4.2b and Table 4.1). Since 
NMR chemical shifts are extremely sensitive to local environments, those associated with 
residues that experience a different environment in two states, for example when located at 
domain interfaces in multimers, are expected not to be the same. Thus, the observed high 
similarity of the spectra, irrespective of the difference in dimer population, suggests that the 
observed signals represent residues that reside in identical local structures of p51 and p66. 
Interestingly, the fact that we observe a large number of resonances in the 1H-15N TROSY HSQC 
spectrum for the p66 homodimer, despite its large molecular mass, suggests that maybe some of 
the smaller domains exhibit a certain degree of independent motion, faster than the overall 
rotational molecular diffusion. 
 
4.3.2 The RNH and Thumb domains are independently folded domains in the p66 
homodimer 
The RNH domain of HIV-RT can exist as a stably folded, individual domain with a structure 
similar to that in the intact protein [169, 173, 193]. It is not known, however, whether other RT 
domains can also exist as stable folded sub-structures.  We, therefore, prepared the Finger-Palm 
domain (residues1 to 216), the Thumb domain (residues 237 to 318) and the RNH domain 
(residues 427 to 556, see Figure 4.1c). The 1H-15N HSQC spectra for all three isolated domains 
exhibit well-dispersed resonances, indicative of stably folded structures (Figure 4.2c-e).  To 
qualitatively assess whether the domain structures within p66 and in isolation are identical, the 
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isolated domain spectra were individually superimposed onto the spectrum of p66 (Figure 4.2c-
e). Amide resonances that were considered identical in frequencies (0.03 ppm in the combined 
chemical shift in Equation 1) were counted: of the three domains, the isolated Thumb and RNH 
domains exhibited large degrees of identity with the intact p66 protein (>40%), while for the 
finger-palm domain it was low (18%, Table 4.1). When comparing the spectra of the individual 
domains with their counterparts in p51, a high degree of resonance frequency identity was 
observed for the thumb domain (55 %). We also evaluated whether, by chance, any spectral 
similarity exists between the structurally diverse RNH and thumb domains; gratifyingly no 
overlap was noted, as can be appreciated from the superposition of their spectra onto the p66 
spectrum (compare the orange and green resonances in Figure 4.4a).  Likewise, p51 and RNH 
domain resonances do not coincide (18 % identity, compare the cyan and orange resonances), 
whereas significant overlap occurs for p51 and p66 (compare the cyan and dark blue resonances 
in Figure 4.4b). Overall, the superposition up to 20 % is explained by signal overlap at the 
crowded regions in the spectra while those above 20 %, such as comparison of the isolated RNH 
domain signals with those in p66 likely indicates structural similarity between the two.  
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Figure 4.4 Superposition of 1H-15N HSQC  
a) of the thumb domain (green) and of the RNH domain (orange) onto the p66 spectrum (dark blue) and 
b) of the p51 domain (cyan) and the RNH domain (orange) onto the p66 spectrum (dark blue). Several 
resonances are labeled with amino acid names and numbers in the insets.   
 
Since no structure is available for the isolated Thumb domain and it was not clear a priori 
whether the isolated domain has the same conformation as the Thumb domain in the p66 
homodimer, we used NMR to investigate this question. Backbone assignments were obtained for 
a sample of the isolated domain and qualitatively assessed using CSI and TALOS+ [102, 181, 
188]. The derived secondary structure elements (α-helices) are consistent with an overall domain 
structure similar to the one observed in the p66/p51 RT crystal. Likewise, Cα chemical shifts 
that were predicted using Sparta, [189] based on the coordinates of the Thumb domain in the RT 
heterodimer crystal structure (PDB = 1DLO [38]), match the experimental ones of the isolated 
Thumb domain (Chapter 5). The similarity in secondary structure elements, and probably the 
tertiary structure, for the Thumb domain alone and in the p66 homodimer is further inferred from 
the resonance overlap noted above (59%, Table 4.1). 
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Table 4.1 Percentage of amide resonances in the spectra of individual isolated domains that reside at identical 
frequencies in the p66 or p51 Spectrum 
 
 p51 RNH thumb finger-palm 
Total number of counted resonances 
in each spectrum  219 119 83 179 
Percentage of signals in the 
individual domain spectra that 
coincide with those in p66  
62 % 40 % 59 % 18 % 
Percentage of signals in the 
individual domain spectra that 
coincide with those in p51  
- 18 % 55 % 18 % 
Resonances were assumed to be identical if they resonated within 0.03 ppm (see “Experimental Methods”).  
 
The combined results imply that the Thumb and RNH domains within the p66 
homodimer and the Thumb domain in the p51 exhibit the same overall structures as the isolated 
domains. This, however, is not the case for the Finger-Palm region (Table 4.1). For this domain, 
notable chemical shift differences were observed in the p66 homodimer, possibly due to local 
structural changes or altered domain-domain or subunit-subunit interactions.  
 
4.3.3 Conservation of the p51-RNH processing site conformation in p66 
The conformation of the p51-RNH processing site (F440↓Y441) in the p66 homodimer was 
assessed based on the comparison of the amide resonance frequencies in the 1H-15N HSQC 
spectrum of the p66 homodimer and those in the isolated RNH domain [193, 194]. Backbone 
amide resonances from residues in the β-1 strand, which contains the processing site in the 
isolated RNH domain, were essentially identical (amino acids 438 to 447) and several of these 
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(I434, F440, and Y441) are labeled in the Figure 4.4b inset. The fact that no chemical shift 
differences were noted for these processing site residues suggests that they are similarly located 
in a β-strand within the p66 homodimer Figure 4.4. Since NMR resonance frequencies are 
highly sensitive to local electronic and conformational influences, the close match between 
amide resonances for the p51-RNH processing site in the p66 homodimer and the isolated RNH 
domain indicates that the site is similarly structured in both. We also did not observe a 
significant number of random coil resonances in the p66 spectrum, making it very unlikely that 
one or both of the RNH domains is unfolded or disordered in the RT p66 homodimer. Since peak 
volumes of these RNH signals are similar or slightly larger than those of the observed indole NH 
signals in the p51 domain in the p66 spectrum (Figure 4.4), a probability that another RNH 
conformation, than that identified in our inspection, exists in the p66 homodimer is low. Even 
with possible exchange between an unfolded and folded RNH domain in p66, any unstructured 
fraction would be <5% of total, given the close match between resonance frequencies for the 
bona-fide folded, isolated RNH domain and the RNH domain in p66. Given all of the above, it is 
strongly suggested that the processing mechanism has to involve the selection of a very minor 
conformer in the overall conformational ensemble by the protease or a local conformational 
change upon protease binding. 
4.4 DISCUSSION 
Numerous p66/p51 RT structures are available, with and without substrate, inhibitors and other 
ligands, allowing for a detailed elucidation of the conformational transitions that are possible in 
the RT heterodimer upon ligand interaction. In all of these structures, differences in domain 
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orientations between the two subunits are observed [36, 39, 170, 195]. In contrast, structural 
information for the p66 homodimer, which is assumed to be the precursor of mature RT [36, 164, 
168, 184], is not available. Therefore, any conformational changes that accompany processing of 
the homodimer into the heterodimer remain ambiguous.  
Here, we investigated the solution conformation of the p66 homodimer, aimed at 
providing the basis for elucidating RT heterodimer formation. We showed that the 1H-15N 
TROSY HSQC spectrum of the p66 homodimer contains a very large number of backbone amide 
resonances, a rather surprising finding for a protein with a molecular mass of 132 kDa. This 
suggests that some of the smaller domains exhibit a certain degree of independent motion, faster 
than the overall rotational molecular diffusion. Our study also establishes that the overall major 
structures of the Thumb and RNH domains within the p66 homodimer are very similar to those 
of the isolated domains.  In addition, the high similarity in chemical shifts for the p51-RNH 
processing site in the isolated RNH domain and the p66 homodimeric RT indicates that the 
cleavage site in the p66 homodimer exhibits essentially the same conformation as the isolated 
RNH domain, seemingly buried in the β-structure of the domain.  
The mechanistic details involved in the formation of the mature RT p66/p51 heterodimer 
are not well understood, but several models have been proposed.  One prevailing model assumes 
that cleavage of the immature p66 homodimer occurs in an unstructured RNH domain (Figure 
4.1c) [169, 170], with subsequent folding of the remaining p66-RNH domain into the structure of 
the mature heterodimeric RT. This hypothesis is based primarily on the assumption that p51-
RNH processing would be very inefficient if the processing site were located within a structured 
domain [196]. Another proposal assumes that the p66 homodimer exists in an asymmetric 
conformation [166, 168]. Indeed, the p51 domain conformation in the p66 subunit differs from 
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that in the p51 subunit of the mature RT heterodimer, and this could be true in the p66 precursor 
as well. A third proposal suggests cleavage of p66 monomers, followed by folding of both p66 
and p51 monomers, and formation of a mature p66/p51 heterodimeric RT (a concerted model) 
[163, 164]. While our NMR results do not allow us to propose an exclusive model, they do 
provide insight into the conformational characteristics in the RT homodimer, thereby limiting 
possible maturation scenarios. First, the observation that the p66 NMR spectrum is a composite 
of those of the folded sub-domains indicates that p66, whether monomer or homodimer, is folded 
in solution. Second, we found that the RNH domain is structured in the p66 homodimer, with a 
conformation essentially identical to that seen in the isolated RNH domain, not altered by 
domain-domain contacts.  Third, none of our data suggests that there are different conformations 
in the two p66 subunits of the homodimer.  
 
Figure 4.5 Possible RNH conformations in the p66 homodimers conformations as maturation precursors 
a) the RNH domains are unfolded or disordered, b) there is conformational difference between the two 
RNH domains, c) both RNH domains in the two subunits are folded. Our data support c).   
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Our observation of a structured RNH domain in the p66 homodimer is consistent with 
previous biochemical results. Protease predominantly processes p66 at the p51-RNH processing 
site (F440-Y441), compared to other processing sites within the RNH domain in the p66 
precursor (Y483-L484, N494-I495, and Y532-L533), and removal of the RNH domain does not 
involve multiple cleavages [23, 167]. Since our data show that the RNH in the p66 homodimer is 
folded, this explains why other protease cleavage sites are not used and only the authentic p51-
RNH site is cleaved.  
In the current study, NMR signals in finger-palm and connection domains were not 
assigned. Thus, our data cannot rule out a model in which the p66 homodimer exists in an 
asymmetric conformation. However, we can rule out a model in which the predominant (>90 %) 
conformation of the RNH domain is different in the two subunits of the p66 homodimer. Even if 
in solution a small free energy difference between the two RNH domains may exist that could 
give rise to two different conformations (conformational substrates) for very short times, the 
overall conformational equilibrium will most likely yield an average conformation over longer 
times. Thus, both domains will adopt the same average energy state, even if two energetically 
distinct conformations, separated by a low energy barrier, exist. In addition, while our 
manuscript was under review, Zheng, et al. published a study on HIV-RT [197]. These authors 
suggest, using Ile methyl signals as probes, that selective unfolding of one of the RNH domains 
in the p66/p66 homodimer occurs. Based on our data, we believe that major disruption of the 
RNH structure is unlikely, although local or temporal unfolding of a small region around the 
processing site cannot be ruled out. 
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4.5 CONCLUSION 
Our results support maturation models that involve folded, rather than unfolded or disordered 
RNH domains (Figure 4.5). This is somewhat surprising since the p51-RNH cleavage site has to 
be processed by the protease, and thus needs to be available for binding. However, as pointed out 
above, if a minor conformation (<5 %) were present, this may have eluded detection, given the 
limited sensitivity and signal overlap in the spectra. Indeed, at present we suggest that such a 
minor conformation of the p51-RNH processing site can be selected or induced by the protease.  
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5.0  NMR STRUCTURE OF THE HIV-1 RT THUMB SUBDOMAIN 
Here, we report the solution NMR structure of the isolated thumb subdomain of HIV-1 reverse 
transcriptase (RT). A detailed comparison of the current structure with dozens of the highest 
resolution crystal structures of this domain in the context of the full-length enzyme reveals that 
the overall structures are very similar, with only two regions exhibiting local conformational 
differences. The C-terminal capping pattern of the αH helix is subtly different, and the loop 
connecting the αI and αJ helices in the p51 chain of the full-length p51/p66 heterodimeric RT 
differs from our NMR structure due to unique packing interactions in mature RT. Overall, our 
data show that the thumb subdomain folds independently and essentially the same in isolation as 
in its natural structural context. The results presented in this chapter have been adapted from: 
Sharaf NG1, Brereton AE2, Byeon I-JL1, Karplus PA2, Gronenborn, AM1. NMR structure of the 
HIV-1 reverse transcriptase thumb subdomain. (submitted to the Journal of Biomolecular NMR).  
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5.1 INTRODUCTION 
RT is an essential protein in the viral life cycle and a major drug target [198-200]. Previous 
crystallographic studies have shown that mature HIV-1 RT is an asymmetric heterodimer, 
composed of two subunits, p66 and p51. The p66 subunit contains two enzymatically active 
units: the polymerase and RNH domains. The polymerase domain is divided into subdomains 
named fingers, palm, thumb, and connection [36]. The names of the first three subdomains were 
inspired by the shape of the p66 subunit of this and related polymerases, in which the spatial 
arrangement of the thumb, fingers and palm subdomains resembles a right hand ready to clasp a 
piece of DNA. The p51 subunit shares the same sequence as the p66 subunit but lacks the RNH 
domain. The finger, palm, thumb and connection subdomains are also present in p51, although 
they exhibit different spatial arrangements from those in the p66 subunit (Figure 5.1) [37, 38, 
40, 49]. 
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Figure 5.1 Overall HIV-1 RT structure 
a) Tube representation of apo-RT (PDB ID: 1DLO), with the p66 and p51 subunits shown in thick and 
thin tube representation, respectively. b) Schematic diagram of (sub)domain organization of HIV-1 RT. 
The palm, fingers, connection, thumb and RNH (sub)domains in a) and b) are colored in red, blue, 
yellow, green and orange, respectively. 
 
At present, the precise mechanism of HIV-1 RT maturation has not been elucidated. 
Based on model system data, a dimeric p66 immature precursor is formed first, which is 
subsequently cleaved at the p51-RNH processing site on one of the p66 subunits. This removes 
the RNH domain and generates the p51 subunit [168, 196, 201, 202]. No atomic structures of the 
p66:p66 immature precursor are available, although several maturation models for HIV-1 RT 
have been proposed [169, 170, 196, 197]. In addition, numerous biochemical/biophysical data 
characterizing the properties of the immature precursor exist [184, 203-208]. The p66 immature 
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precursor and mature HIV-1 RT exhibit similar polymerase and RNH activities, but differ in 
their inter-subunit affinity [209]. The mature HIV-1 RT (i.e a p66:p51 heterodimer) is a tighter 
dimer with a dissociation constant (Kd) of 0.23 µM, while the Kd for the p66:p66 immature 
precursor is 4.4 µM [210].  
To structurally characterize RT maturation, we previously investigated the conformation 
of the p66 homodimer by solution NMR [208]. Given the protein’s large size (132 kDa), NMR 
studies of the p66 immature precursor are challenging. However, using TROSY-type 1H-15N 
HSQC spectroscopy, it was possible to assess the structures of the (sub)domains within the p66 
immature precursor and the isolated (sub)domains of HIV-1 RT. 1H-15N HSQC resonances of the 
isolated HIV-1 thumb subdomain superimposed well with the equivalent resonances in the 1H-
15N HSQC spectrum of the homodimer, suggesting that the thumb domains in the p66 immature 
precursor exhibit very similar conformations as the isolated thumb domain [208]. Here, we 
extend this work by reporting the solution structure of the isolated HIV-1 RT thumb subdomain, 
and showing that it too is very similar to the crystal structures of the thumb domains in the 
mature RT.  
5.2 EXPERIMENTAL PROCEDURES 
5.2.1 NMR spectroscopy 
Uniformly 15N- and 13C,15N-labeled proteins were buffer exchanged into 25 mM sodium 
phosphate, 100 mM NaCl, 10% v/v D2O, pH 6.8 in an Amicon Ultra concentrator (EMD 
Millipore) to a final volume of 350 µL and final protein concentration of 1.0 mM. All NMR 
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spectra were acquired at 30 °C on Bruker AVANCE600 and AVANCE700 spectrometers, 
equipped with 5 mm triple resonance, Z-axis gradient cryoprobes (Bruker Biospin, Billerica, 
MA). Backbone and side chain resonance assignments were carried out using two-dimensional 
(2D) 1H-15N HSQC, three-dimensional (3D) HN(CO)CACB, HNCACB, H(CCCO)NH, 
C(CCO)NH, HCCH-TOCSY spectra [86]. Distance restraints were derived from 3D 
simultaneous 13C- and 15N-edited NOESY spectra [211], using a mixing time of 0.15 s. All NMR 
data were processed with TOPSPIN 2.1 or 3.1 (Bruker) and NMRPipe [187], and analyzed with 
Collaborative Computing Project for NMR (CCPN) analysis program [212]. 
5.2.2 NMR structure calculation 
Structure calculations were performed using the anneal.py protocol in XPLOR-NIH [213]. An 
iterative approach with extensive manual cross-checking of all distance restraints against the 
NOESY data and intermediate structures was employed using CCPN analysis. The final number 
of the NMR-derived restraints was 2,782, with 2,620 NOE distances, 46 H-bond distances 
identified from NOE patterns for α-helices and β-sheets, and 116 φ and ψ backbone torsion 
angles from TALOS+ calculations [214]. Two hundred and fifty six structures were generated 
and the 30 lowest energy structures were selected and analyzed using PROCHECK-NMR [215] 
and MolProbity [216]. Atomic coordinates of the structures have been deposited in the Protein 
Data Bank with accession code 5T82, and chemical shift assignments have been deposited in the 
Biological Magnetic Resonance Data Bank accession number 30171. Structures were visualized 
with MOLMOL [217] and VMD [218].  Structural figures were generated using UCSF Chimera 
[219]  and the PyMOL Molecular Graphics System, Version 1.8 [220]. 
 52 
5.2.3 Ensemblator comparisons of NMR and crystal structure ensembles 
A representative set of high-resolution RT crystal structures, refined at a resolution of 2.4 Å or 
better, was selected from all deposited structures. This yielded the following set of 28 PDB 
entries: 1RTJ, 1S1T, 2OPS, 2RKI, 2YKN, 2YNF, 2YNG, 2ZD1, 3BGR, 3DLG, 3DLK, 3LAK, 
3LP1, 3MEC, 3MEE, 3QIP, 3T1A, 4DG1, 4I2P, 4ID5, 4IDK, 4IFV, 4IFY, 4IG3, 4KFB, 4KO0, 
4KV8, and 5D3G. Analyses were carried out using Ensemblator version 3 
(https://github.com/atomoton/ensemblator; Brereton and Karplus, unpublished), a greatly 
enhanced version of the recently described general ensemble-ensemble comparison program 
[221]. The Ensemblator “Prepare” stage was used to combine the 30-member NMR ensemble 
with all the crystal structures to generate a file that contained all of the backbone and side-chain 
atoms that were in common between the NMR models and the 28 individual p51 and p66 chains 
from the X-ray structures. For all Ensemblator “Analysis” stage runs, a distance cutoff of 2 Å 
was used to define “core” atoms; with this cutoff, 26.9 % of the atoms in the ensemble qualified 
for the common-core, which was used to guide the global best-fit. Based on these best-fit 
models, two automated clustering methods inherent to the program were used, as well as a 
“manual” approach, in which the NMR models, the p51 chains and the p66 chains were 
separated into three groups.  
For each comparison, the standard Ensemblator output [221] included residue-level plots 
of the global and local comparisons for each pair of groups. In order to identify the most 
significant/consistent regions of similarity and any differences between a given pair of grouped 
structures, a residue-level “silhouette index” was calculated with Ensemblator v3. This index 
combines both global and local comparison information. For each of the two groups in a given 
M,N pair of grouped structures, every atom’s global silhouette score is calculated as the mean 
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pairwise distance between the groups minus the mean pairwise distance within the group, 
divided by the larger of the two values: (<dinter>-<dintra>)/max(<dintra>,<dinter>). The silhouette 
scores for each atom are averaged across the two groups, and a residue-based value is obtained 
by averaging the values for the N, CA, C', and O atoms of each residue. A second silhouette 
score for comparing local backbone conformations is similarly calculated for each residue based 
on the “locally-overlaid dipeptide residual” (LODR) distances [221]. The final “silhouette index” 
for a residue is the average of the global and local silhouette scores. The level of detectable 
difference between the groups increases with the index as it goes from near 0 to 1. For indices 
0.4 – 0.6, we have considered the groups to be neither notably similar nor different; within this 
range, more fine clustering may permit the identification of subgroups with some differences.   
 
5.3 RESULTS AND DISCUSSION 
5.3.1 Solution structure of the HIV-1 RT thumb domain 
The 1H-15N HSQC spectrum of the thumb subdomain exhibits well-dispersed resonances (Figure 
5.2a), indicative of a well-folded structure. Near complete (> 95 %, backbone and side chain) 
NMR assignments were obtained. A superposition of the backbone atoms (N, Cα, and C’) of the 
final 30-member ensemble is shown in Figure 5.2b. A summary of structural statistics is 
provided in Table 5.1, demonstrating that the core domain structure is well defined with an 
average atomic root mean square deviation (RMSD) of 0.45 ± 0.05 Å and 0.97 ± 0.08 Å for the 
backbone and all heavy atoms (residues 246-314). Figure 5.2c displays the lowest energy 
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structure in ribbon representation, illustrating the architecture of the protein. As seen in RT 
crystal structures, the fold of the thumb domain consists of three α-helices, commonly named 
αH, αI, and, αJ [36] that are linked together by loop regions that lack regular secondary 
structure. In the solution structure of the isolated thumb domain determined here, the core of the 
structure similarly comprises three α-helices, with αH (254-270), αI (278-285), and αJ (297-
311). The greatest backbone variation in the ensemble occurs at the two termini and the 285-295 
loop between αI and αJ. 
 
Figure 5.2 Assignments and solution structure of the thumb subdomain  
a) 600 MHz 1H-15N HSQC spectrum at of the thumb subdomain (1.0 mM protein in 25 mM sodium 
phosphate, 100 mM NaCl, pH 6.8). The two resonances (Q278 and N306) that are located outside the 
displayed spectral range are shown in insets. b) Stereoview of the final 30 conformer ensemble (N, Cα, 
and C’, residues 240-315). Regions of helical structure are colored in green and the remainder of the 
structure in grey. c) Ribbon representation of the lowest energy structure using the same color scheme as 
in b.  
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Table 5.1 Table 1.  Statistics for the final 30 conformer ensemble of the thumb subdomain of RT 
Number of NOE distance restraints  
     Intra-residue (i-j=0) 1091 
     Sequential (|i–j|=1) 617 
     Medium range (2≤|i-j|≤4) 456 
     Long range (|i-j|≥5) 456 
     Total 2620 
Number of hydrogen bond restraints 46 
Number of dihedral angle restraints   
φ 59 
ψ 57 
Total 116 
Structural Quality  
Violationsa  
     Distances restraints (Å) 0.029 ± 0.001 
     Dihedral angles restraints (°) 0.431 ± 0.091 
Deviation from idealized covalent geometry  
Bond lengths (Å) 0.003 ± 0.000 
Bond Angles (°) 0.478± 0.010 
Improper torsions (°) 0.302 ± 0.012 
Average RMSD of atomic coordinates (Å)b  
Backbone heavy atoms 0.45 ± 0.05 
All heavy atoms 0.97 ± 0.08 
Ramachandran plot analysis (%)c   
Favored regions 77.3 ± 3.0 
Allowed regions 95.8 ± 1.9 
a No individual member of the ensemble exhibited distance violations  > 0.5 Å or dihedral angle violations >5°. 
b The average RMSD of atomic coordinates for residues 246-314 was calculated for individual structures with respect to the 
mean structure. The terminal regions (residues 237-245 and 315-326) were excluded from the statistics. 
c Statistics were calculated using MolProbity for residues 246-314; of the 4.2% of residues in disallowed’ regions, all are 
near the allowed/disallowed borders 
 
5.3.2 Comparisons with crystal structures of the thumb domain in the context of HIV-1 
RT  
The structure of HIV-1 RT thumb domain in the context of the full-length protein was first 
determined using X-ray crystallography [36] (Figure 5.1a) and since then has been seen in over 
100 crystal structures deposited in the PDB. In the p66 subunit, the thumb subdomain interacts 
mostly with the connection domain in the same subunit and is poised to make extensive 
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interactions with DNA. In the p51 chain, the thumb subdomain similarly interacts with its own 
connection domain but also packs against the RNH domain of the p66 subunit (Figure 5.1). 
Although the thumb subdomains in p66 and p51 are found in different positions in the mature 
enzyme, their structures are quite similar, and both contribute to binding and positioning of 
nucleic acid substrates [37, 39, 222]. In the crystal structure of HIV-1 RT bound to DNA, αH of 
p66 interacts with the sugar-phosphate backbone of the primer strand, while the antiparallel αI 
interacts with the template strand [39]. In p51, in which the thumb subdomain is located next to 
the RNH domain of p66, the thumb domain forms the “floor” of the nucleic acid binding cleft, 
contributing to RNA/DNA binding [37, 39, 57, 222]. Amino acid changes in the αH and αI 
helices were shown to affect DNA binding, DNA synthesis, and frameshift fidelity [223-227]. 
αH and αI are part of the helix-turn-helix segment, termed the “helix clamp” motif, with similar 
motifs found in many eukaryotic, prokaryotic and viral nucleic acid polymerases [227].  
In terms of overall chain-fold, the isolated domain NMR solution structure presented here 
(Figure 5.2b,c) is similar to the crystallographic subdomain structures in over 100 available 
crystal structures of the p51 and p66 chains of heterodimeric HIV-1 RT (Figure 5.3a,b). Within 
the complete set of RT crystal structures, many structures are of moderate resolution (3 Å or 
lower), and, in such structures, the conformational details are less reliable; we, therefore, selected 
a high-resolution subset of 28 RT crystal structures, determined at 2.4 Å resolution or better. 
This set was subjected to analysis by the Ensemblator [221] to identify systematic and significant 
differences between the NMR thumb domain structure and the p51 and p66 X-ray thumb domain 
structures. Automatic clustering by the Ensemblator separated the full set of models into distinct 
groups, also containing exclusively the NMR structure or the p51 or p66 thumb domain crystal 
structures. Therefore, we carried out our final analyses by manually defining these as distinct 
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groups. The key Ensemblator output for a given comparison of two groups consists of a pair of 
plots that reflect the global and local conformational differences, respectively. In each plot, the 
intra-group variations are compared with the inter-group variation and the closest approach 
between the groups (Figure 5.4, upper and middle panels). The regions of greatest systematic 
difference are characterized by high silhouette index values (Figure 5.4, lower panels), which 
contain information from both the global and local comparisons. 
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Figure 5.3 Comparison between the NMR structure of the isolated thumb domain and the thumb domain in 
the p51 and p66 chains in X-ray structures of the heterodimeric HIV-1 RT 
a) Backbone superposition of p51 thumb domain X-ray structures and the mean NMR structure (cyan), 
with atoms in the X-ray structures colored from blue to red with increasing RMSD values. b) Equivalent 
superposition as in a), but for the p66 thumb domain X-ray structures. c) Detailed view of residues 265-
271, including the side chain of Ser268, for conformers in the NMR ensemble (orange carbons), p51 
chains (blue carbons) and p66 chains (green carbons). d) Hydrogen bonds between the H-atom of the 
donor (sphere) and the backbone oxygen acceptor in the NMR (orange), p51 (blue), and p66 (green) X-
ray structures of the region shown in panel c). e) Ribbon diagram of the p51 thumb domain (light blue) 
from a representative RT crystal structure (PDB Code 4IFY), with residues 285-287 depicted in blue. The 
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remainder of p51 and p66 is shown in blue and red, respectively. The NMR ensemble (grey) differs from 
the X-ray structure around residue 287, where the p51 thumb subdomain contacts p66. F) Ribbon 
diagram of the p66 thumb domain (pink) in a representative RT crystal structure (PDB Code 4IFY), 
highlighting the solvent exposed position of residues 285-287 (red coil) . The remainder of the p66 chain 
is shown in red surface representation. In the NMR ensemble (grey), a similar local conformation is seen 
for residues 285-287. 
 
In addition to some differences that occur near the N- and C-terminal residues extending 
from the core of the domain (<254 and >310), the silhouette indices reveal two areas of 
consistent differences (> ~0.6 Å) between the NMR and crystal structures (Figure 5.4a,b lower 
panels). One is near residue 270 and applies to the NMR group as compared to both the p51 and 
p66 thumb domain groups. The second is around residues 285-295 and applies to the NMR 
ensemble as compared to the p51 group, but not the p66 group (Figure 5.4). In both of these 
regions, no individual member of the NMR ensemble is closer than 1 Å to any member in the 
crystal structure ensembles, either globally or locally (red traces in Figure 5.4a,b upper and 
middle panels). In both cases, these emerged as real differences between the conformation of the 
isolated thumb subdomain and in the mature p66:p51 heterodimer. 
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Figure 5.4 Comparison between the NMR ensemble and the collection of 28 p51 and p66 thumb domain 
crystal structures 
a) NMR vs. p51. b) NMR vs. p66. c) p51vs. p66. For each pair of groups, global (upper panels), and local 
(middle panels) comparisons are shown, along with a Silhouette Index (lower panels; black trace) plot 
that identifies the regions with significant differences (above the grey strip) and similarities (below the 
grey strip). In the global and local comparison plots, the colors are as follows: NMR average backbone 
intra-group pairwise RMSD (orange), p51 average backbone intra-group pairwise RMSD (blue), and p66 
average backbone intra-group pairwise RMSD (green) are shown along with average backbone inter-
group pairwise RMSDs (pale purple) and closest approach distances (red). A secondary structure 
diagram (based on PDB entry 1RTJ [50]) indicates α-helical (red), PII-helical (blue), and other (green) 
segments.  
 
The difference near residue 270 involves the last turn and C-terminal capping of the αH 
helix. In this segment, in all of the NMR conformers, the transition from an α- to a 310-helix 
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occurs at residue 267, with hydrogen bonds between 269-N … 265-O, 270-N … 267-O and 271-N 
… 268-O. In contrast, in all of the crystal structures this transition occurs one residue earlier and 
the structures contain H-bonds between with 269-N … 266-O and 271-N … 267-O, along with a 
side chain-backbone H-bond from Ser268 Oγ to 265-O (Fig 3c,d). We carefully examined this 
difference and ascertained that indeed it is real; the observed NMR NOE pattern is incompatible 
with the 271-N … 267-O H-bond seen in the crystal structure, although the cause for this 
discrepancy is not clear. Inspection of this region in the p51 and p66 chains in the crystal 
structures shows diverse (i.e. subunit and crystal form-dependent) packing interactions with 
either distant parts of the chain or across crystal contacts. For example, the structural contexts of 
the p66 and p51 thumbs are distinct: the p66 helical cap packs against and makes H-bonds with 
the connection domain near residue 345, but this part of the p51 helix is more exposed while the 
sidechain of Ile270 packs deeply into a hydrophobic pocket that also includes Phe346 and 
Trp426. Because these interactions are not uniform and present in all structures, it is hard to 
ascertain whether and how they may influence the helix capping pattern. One set of interactions 
that is common between p66 and p51 involves side chain packing of Tyr271 against residues 310 
through 314. These interactions are also similar in the isolated domain NMR structure, thus do 
not appear responsible for the difference between the X-ray and NMR structures. 
The difference between the p51 and p66 thumb domains near residue 285 can easily be 
rationalized by the unique context of the p51 chain in the heterodimeric RT. In p51, the 285-295 
loop between αI and αJ packs against the surface of p66 (Figure 5.3e), with a consistent 
hydrogen bond between the Lys287 backbone oxygen and Tyr441-OζH of the p66 chain. By 
contrast, in the p66 thumb domain, this loop is fully exposed to solvent in some crystal forms 
(e.g. Figure 5.3f) or involved in crystal contacts in others. This results in a number of diverse 
 62 
conformations that vary over ~3 Å among the different crystal structures. This spread is larger 
than the ~2.5 Å backbone intra-group RMSD observed in the NMR ensemble (Figure 5.4b 
upper panel). Although the local conformation in this area is somewhat similar between the 
NMR ensemble and the p66 crystal structures, there appears to be a global shift of ~1 Å (Figure 
5.3f). Interestingly, there is a low silhouette index near the 285 region, when p51 and p66 crystal 
structures are compared (Figure 4c), indicating that no large consistent difference is present; this 
occurs because among the broad conformations sampled in the p66 chains, some structures adopt 
a conformation similar to that seen in p51.  
5.4 CONCLUSION 
We previously suggested that the structure of the isolated HIV-1 thumb subdomain resembles 
that of the thumb domains in the p66 immature precursor, based on a qualitative comparison of 
their 1H-15N HSQC spectra [208]. Here, we directly confirm that the NMR structure of the 
isolated HIV-1 thumb subdomain is very similar to the thumb domain in X-ray structures of 
mature RT, albeit with two regions of interesting local conformational difference. One pertains 
to the C-terminal capping pattern of the αH helix, with no apparent cause. The other involves the 
loop conformation between the αI and αJ helices in the p51 chains. This most likely originates 
from unique packing interactions of the p51 thumb domain in mature RT that are not present in 
the isolated domain. Taken together, we show that the thumb subdomains in the mature RT and 
the p66 immature precursor are independent units that can fold autonomously and exhibit very 
similar structures, whether in isolation or present in its two different natural structural contexts 
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(p51 or p66). Our data also underscore the well-known fact that surface regions are malleable 
and are influenced by context.  
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6.0  THE CONFORMATIONAL PLASTICITY OF HIV-1 RT  
HIV-1 reverse transcriptase (RT) is a major drug target in the treatment of HIV-1 infection.  RT 
inhibitors currently in use include non-nucleoside, allosteric RT inhibitors (NNRTIs), which bind 
to a hydrophobic pocket, distinct from enzyme's active site. We investigated RT-NNRTI 
interactions by solution 19F NMR, using singly 19F labeled RT proteins. Comparison of 19F 
chemical shifts of fluorinated RT and drug-resistant variants revealed that the fluorine resonance 
is a sensitive probe for identifying mutation-induced changes in the enzyme.  Our data show that 
in the unliganded enzyme, the NNRTI-binding pocket is highly plastic and not locked into a 
single conformation. Upon inhibitor binding, the binding pocket rigidifies.  In the inhibitor-
bound state, the 19F signal of RT is similar to that of drug-resistant mutant enzymes, distinct from 
what is observe for the free state. Our results demonstrate the power of 19F NMR spectroscopy to 
characterize conformational properties using selectively 19F labeled protein.  The results 
presented in this chapter have been adapted from: Sharaf NG, Ishima R, Gronenborn AM (2016) 
Conformational Plasticity of the NNRTI-Binding Pocket in HIV-1 Reverse Transcriptase: A 
Fluorine Nuclear Magnetic Resonance Study. Biochemistry-Us 55:3864–3873.  
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6.1 INTRODUCTION 
HIV-1 reverse transcriptase (RT) is an essential enzyme in the HIV-1 lifecycle and a major drug 
target in the treatment of HIV-1 infection. Current FDA approved RT inhibitors are effective, but 
continuous treatment can lead to the emergence of drug resistant strains [3]. Understanding RT, 
its structure, and the mechanism of inhibitor action, is important for the development of novel 
inhibitors with more favorable resistance profiles. A large number of crystal structures of RT are 
available (wild-type and mutants), providing valuable information on the protein's conformations 
as well as drug interactions [36, 38, 46, 47, 49, 54, 55, 228]. Crystallographic studies have shown 
that RT is an asymmetric heterodimer that comprises two subunits p66 and p51. The p66 subunit 
contains two domains, a polymerase, and RNH domain. The p51 subunit is identical in amino 
acid sequence to p66, apart from lacking the C-terminal RNH domain. The polymerase domain 
of each subunit is further subdivided into fingers, palm, thumb, and connection subdomains [36]. 
In the overall dimeric RT structure, the subdomains in the p51 and p66 subunits exhibit different 
relative orientations (Figure 6.1a). 
Although highly effective as RT inhibitors and the first drugs to treat HIV-1 infection, 
nucleoside/nucleotide RT inhibitors, which act as chain terminators in the enzymatic reaction, 
are associated with numerous side effects. Therefore, non-competitive RT inhibitors were 
developed and have been in the clinic for almost 20 years [5, 25, 198-200, 229]. These NNRTIs 
include NVP, EFV, ETR, and RPV. Although chemically diverse, they all bind to the same 
pocket, distinct from the polymerase active site, and inhibit RT allosterically [59, 199]. A 
comparison of the crystal structures of apo-RT and RT in the presence of NNRTIs reveals 
significant structural changes upon NNRTI binding. Apo-RT adopts a “closed” conformation, in 
which the p66 thumb subdomain folds down onto the fingers subdomain. In contrast, in the 
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presence of NNRTIs, RT adopts an “open” conformation, in which the p66 thumb domain is ~30 
Å away from the fingers subdomain (Figure 6.1b). Local conformational differences are also 
seen in the NNRTI-binding pocket in the p66 subunit. This pocket is not present in apo-RT, 
where the Y181 and Y188 side chains fill most of the cavity, which is occupied by the NNRTI in 
the NNRTI/RT complex (Figure 6.1c)[36, 38, 46, 49]. 
Crystal structures are invaluable for pinpointing structural details of enzyme-inhibitor and 
substrate interactions, however, studies by other methods can offer complementary information. 
For RT, only a limited number of investigations in the absence of nucleic acid substrates have 
been reported, including EPR experiments and hydrogen exchange mass spectrometry 
(HXMS)[230, 231]. Also, a few solution NMR studies, using [methyl-13C]-methionine or 
isoleucine labeled RT have been reported [177, 207]. In addition, several computational studies 
have been conducted to characterize RT dynamics and the effects of NNRTI binding [232-239]. 
Yet, a general consensus on the mechanistic basis for NNRTI inhibition of RT has not been 
reached [5, 36, 50, 240]. 
Here, we used 19F solution NMR to study RT in solution by incorporating a single 
fluorine probe into the enzyme. Single site labeling prevents resonance overlap and enables 
simple and fast 1D NMR experiments. The fluorine nucleus was selected since it possesses a 
high gryomagnetic ratio, which results in excellent sensitivity (83% of 1H). In addition the 19F 
shielding is dominated by a large paramagnetic term, which makes it exquisitely sensitive to its 
local environment (the 9F chemical shift range is ~100 fold larger than that of 1H) [129, 130, 
153]. 
In particular, we aimed to gain insight into the characteristic dynamics of the NNRTI-
binding site, mechanism of action of NNRTIs, and the effects of drug resistant mutations. For 
 67 
this study, RT was labeled site-specifically with 4-trifluoromethylphenylalanine (tfmF) at 
positions 127, 146 and 181, producing three singly labeled RT proteins named RT127tfmF, 
RT146tfmF, and RT181tfmF, respectively. Comparisons of the 19F spectra of RT127tfmF, 
RT146tfmF, and RT181tfmF showed that distinctly different chemical shifts are observed for the 
trifluoromethyl group, demonstrating that the 19F probes in each RT protein are in distinct 
environments. Furthermore, linewidth analyses of these spectra suggest that the NNRTI-binding 
site is highly plastic in the ligand-free enzyme. Mutant, drug resistant proteins V108I, K103N, 
and E138K all modulate the conformational plasticity or average chemical environment of the 
NNRTI-binding site, with the K103N mutation producing the most prominent effect.  In the 
presence of NVP, EFV, ETR, and RPV, the conformational plasticity of RT at the NNRTI-
binding site is reduced, and the chemical shift of the NNRTI-bound signals depends on the 
identity of the inhibitor, regardless of the presence of drug resistant mutations. These data show 
that 19F NMR can be used as an effective tool for examining NNRTI -RT interactions.  
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Figure 6.1 General description of RT structure, and comparison of apo and EFV-bound crystal structures of 
RT  
a) Tube representation of apo-RT (PDB: 1DLO), with the fingers, palm, thumb, connection, and RNH 
domains in the p66 subunit colored in blue, pink, green, yellow and orange, respectively. The p51 subunit 
is colored grey. a) Structural differences between apo-RT (left, PDB: 1DLO) and EFV-bound RT (right, 
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PDB: 1FK9 [46]). A large conformational change, including the separation of the thumb and fingers 
domains (indicated by the arrow), is seen in the drug-bound structure. Tyrosine residues 127, 146 and 
181 are depicted in ball and stick representation and encircled.  c) Details of the binding site in apo RT 
and the EFV-bound RT complex, illustrating the rotation of the Y181 (black arrow) and Y188 (grey 
arrow) side chains out of the binding pocket. The bound EFV molecule is shown in green and pertinent 
distances between the benzoxazin-2-one and the backbone carbonyl oxygen of K101 (2.8 Å), and the 
carbonyl group of the bexzoxazine-2-one and the backbone nitrogen of atom K101 (3.2 Å) are indicated. 
6.2 EXPER IMENTAL PROCED URES 
6.2.1 Proteins and reagents 
All proteins were prepared as described in Chapter 3, see Table 3.1. An expanded description of 
each RT protein is also included below.  
The RT127tfmF, RT146tfmF, and RT181tfmF proteins contain a single tfmF in the p66 
subunit of RT at positions 127, 146 and 181, respectively. RT181tfmF-V108I and RT181tfmF-
K103N proteins contain a singl e tfmF residue at position 181 in the p66 subunit, and amino acid 
changes (V108I or K103N) in both, the p51 and p66 subunits. The RT181tfmF-E138K(p51) 
proteins contain a single tfmF at position 181 in the p66 subunit, and the E138K amino acid 
change in the p51 subunit of RT. 
EFV, NVP were kindly provided by Dr. Nicholas Sluis-Cremer. ETR and RPV were 
purchased from Selleckchem (Houston, TX). All NNRTIs were stored in DMSO at 
concentrations of 10 mM. 
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6.2.2 NMR experiments 
Protein samples for NMR  were buffer exchanged into 25 mM sodium phosphate buffer, 100 
mM NaCl, 10% v/v D2O, pH 6.8 in an Amicon Ultra concentrator (EMD Millipore, Billerica, 
MA) to a final volume of 350 µL. All final protein concentrations were ~35 µM. 19F 1D NMR 
spectra with 1H composite decoupling during acquisition were recorded on a 600 MHz Bruker 
AVANCE spectrometer, equipped with a CP TXO F/C-H-D triple-resonance z-axis gradient 
cryoprobe (Bruker Biospin, Billerica, MA). Spectra for the inhibitor-free proteins as well as 
samples containing NVP, EFV, ETR, and RPV at 1:1 and 1:5 RT: NNRTI inhibitor ratios were 
recorded using Topspin 3.1 (Bruker) and analyzed with MestReNova (Escondido, CA). Prior to 
Fourier transformation, the time-domain free-induction decays were apodized with an 
exponential function, using a line broadening factor of 30 Hz. Chemical shifts and linewidths 
were calculated using the peak deconvolution feature in MestReNova. An upper limit of 
uncertainty for the linewidths was qualitatively estimated by assuming that the fit error of each 
peak is associated with the linewidth error. 
6.3 RESULTS 
6.3.1 Spectra of apo-RT127tfmF, apo-RT146tfmF, and apo-RT181tfmF 
19F NMR spectra were recorded for RT127tfmF, RT146tfmF, and RT181tfmF, each containing a 
single tfmF at the indicated position in the p66 subunit of RT (Figure 6.1b). Different spectra 
were observed for the apo-proteins (Figure 6.2Aa-c, black traces), reflecting the distinct 
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environment around the tfmF side chain of each RT protein.  For apo-RT127tfmF, a single 
resonance signal is seen at -61.5 ppm (100 ± 2 Hz; Figure 6.2a), while for apo-RT146tfmF, a 
major signal is observed at -62.0 ppm (150 ± 2 Hz), and a small additional signal is seen at -60.2 
ppm (150 ± 85 Hz), slightly downfield from the major resonance (Figure 6.2b). The spectrum of 
apo-RT181tfmF exhibits a very broad signal at -60.8 ppm (500 ± 5 Hz), much wider than those 
of apo-RT127tfmF and apo-RT146tfmF, and a smaller signal around -61.8 ppm (Figure 6.2c). In 
each spectrum, the major signal clearly originates from the p66/p51 heterodimeric RT. The very 
small signal in Figure 6.2c may originate from the small amount (< 8 %) of p66 monomer and/or 
homodimer in the sample [210]. This was confirmed by comparing spectra of different RT 
samples (data not shown). 
 
Figure 6.2 1D 19F NMR spectra of RT   
4-trifluoromethyl-phenylalanines substituted for tyrosine residues at several positions in the p66 subunit, 
in the absence (black) and presence of EFV at 1:1 and 1:5 molar ratios (light and dark green, 
respectively).19F spectra of a) RT127tfmF, b) RT146tfmF, and c) RT181tfmF at 27°C are shown. 
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6.3.2 EFV binding to RT127tfmF, RT146tfmF, and RT181tfmF 
The effect of EFV binding to the three RT variants, RT127tfmF, RT146tfmF, and RT181tfmF 
was investigated (Figure 6.2). At 1:1 RT:EFV molar ratio, no changes are observed for 
RT127tfmF (Figure 6.2a, light green trace). In contrast, for RT146tfmF, two new signals are 
observed, one very close to the one of the free protein (-62.0 ppm) and the other downfield, at -
61.8 ppm  (Figure 6.2b, light green trace). Both resonances, at -61.8 ppm and -62.0 ppm, exhibit 
comparable linewidths (180 ± 2 Hz). The broad asymmetric signal of RT181tfmF at -60.8 ppm 
(500 ± 2 Hz) disappears upon EFV binding (Figure 6.2c, light green trace) and a new, sharper 
resonance appears at -60.3 ppm (125 ± 2 Hz). Spectra were also recorded at a 1:5 RT: EFV 
molar ratio (Figure 6.2, dark green traces) to ensure saturation of the protein with ligand. For all 
proteins, the spectra at 1:5 are similar to spectra at 1:1 RT:EFV molar ratio, suggesting that 
saturation with EFV is essentially reached at the 1:1 molar ratio, consistent with the Kd value of 
92 nM for EFV binding to the p66/p51 RT heterodimer [203]. 
These spectral data are interpreted in light of the location of the three amino acid residues 
in RT crystal structures [46, 52]. Residue 127 is ~35 Å away from the NNRTI binding site, 
located on the fingers subdomain and pointing towards the solvent (Figure 6.1b), and no 
significant changes in the position of residue 127 in the absence or presence of EFV are noted 
when comparing crystal structures of apo-RT and the EFV/RT complex. The resonance 
frequency of RT127tfmF, which is essentially not affected by EFV binding, is consistent with 
this observation (Figure 6.2a). Residue 146 is ~30 Å away from the NNRTI binding site and is 
also located on the fingers subdomain. However, this residue points towards the thumb domain. 
In the RT146tfmF protein, the 19F probe at position 146 clearly senses EFV binding and splits 
into two resonances, at -60.2 and -61.8 ppm, in the EFV-bound form (Figure 6.2b). The 
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presence of two resonances suggests that the 19F probe in RT146tfmF reports on two 
conformations, one of which is very similar to the free conformation, given that only a very 
small difference in frequency is involved, while the other one reflects a distinctly different 
conformation. The 181tfmF side chain is located in the NNRTI-binding pocket (Figure 6.1b,c) 
and EFV binding, by necessity, is expected to influence its conformation. The spectrum of 
RT181tfmF in the presence of EFV contains a substantially narrower resonance for the inhibitor 
bound state, which is shifted downfield compared to that of apo-RT181tfmF. The broad 
resonance observed in the spectrum of apo-RT181tfmF (500 ± 2 Hz) suggests that the ligand-free 
protein exhibits a substantial degree of conformational plasticity in the NNRTI binding site, 
which is reduced in the EFV/RT complex (Figure 6.2c), evidenced by the significantly narrower 
linewidth of the bound signal (125 ± 2 Hz).  
6.3.3 Drug-resistant variants of RT 
Three drug-resistant variants of RT were selected for investigation. V108I is associated with 
NVP resistance, K103N imparts NVP and EFV resistance,[241-244] and E138K is connected 
with therapeutic failure of ETR and RPV [245-248]. We evaluated these mutants in the context 
of RT181tfmF, since residue 181 resides in the NNRTI site and should report on possible effects 
of these mutations on the protein properties at this binding site.   A superposition of the 19F 
spectra of all three apo RT181tfmF mutants is provided in Figure 6.3. The linewidth of the apo-
RT181tfmF-V108I signal (red, 500 ± 5 Hz) is similar to that of the apo-RT181tfmF (black, 500± 
5 Hz), although slightly upfield shifted, suggesting a minimal influence of this mutation on the 
NNRTI binding site. In contrast, the signal of apo-RT181tfmF-K103N is narrower and downfield 
shifted (purple; 300 ± 15 Hz, -60.1 ppm). This suggests that in this mutant a less plastic 
 74 
conformation is present in the binding site, compared to apo-RT181tfmF. The signal in the 19F 
spectrum of apo-RT181tfmF-E138K(p51) is also broad (green, 600 ± 20 Hz) and is similar to 
that of apo-RT181tfmF, indicating that only small changes are introduced into the flexible 
binding site. Collectively, these data suggest that the local environment around the 19F probe at 
the 181 position of RT is most prominently affected by the K103N mutation.  
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Figure 6.3  1D 19F NMR spectra of RT181tfmF and several RT mutants at 27˚C. 
a) Superposition of the fluorine resonances of RT181tfmF (black), RT181tfmF-V108I (red), RT181tfmF-
E138K(p51) (green), and RT181tfmF-K103N (purple). b) Superposition of the fluorine resonances of 
RT146tfmF (black), RT146tfmF-V108I (red), and RT146tfmF-K103N (purple). All RT181tfmF and 
RT146tfmF variants contain amino acid changes in both the p51 and p66 domains, except for 
RT181tfmF-E138K in which the E138K change is only present in the p51 subunit. 
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6.3.4 NVP, EFV, ETR, and RPV binding to RT181tfmF and mutants associated with 
drug resistance 
To examine the spectral perturbations of NNRTIs on the 19F spectrum of RT181tfmF, we 
recorded spectra in the presence of NVP, ETR, and RPV, in addition to EFV (Figure 6.4a; note 
the panel of Figure 6.2c is included as the 2nd panel in Figure 6.4a for comparison). Spectra 
show that saturation with EFV, ETR and RPV is essentially complete at the 1:1 RT:NNRTI 
molar ratio, while, for NVP, much higher concentrations are needed to ensure saturation. These 
observations are consistent with results obtained in cell-based assays, that show the EC50 for 
NVP, 0.085 µM, is much higher than for EFV, ETR and RPV, which are 0.001, 0.002, and 
0.0004 µM, respectively [58]. Importantly, in the presence of each NNRTI, the defining 
characteristic of each spectrum is the significantly narrower NNRTI-bound signal (Figure 6.4a, 
colored traces), compared to the inhibitor-free signal of apo-RT181tfmF (500 ± 2 Hz) (Figure 
6.4a, black trace) (Table 6.1). This suggests that NVP, EFV, ETR, and RPV all reduce the 
conformational plasticity of the NNRTI inhibitor binding site around position 181, as reflected in 
the narrower linewidth of the tfmF signal. 
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Table 6.1 19F Resonance frequencies and linewidthsa 
 
 a the upper limit of uncertainty in the linewidth was qualitatively estimated as described in Materials and Methods. 
balthough the signal is not symmetric, the resonance frequency and the linewidth were extracted assuming a single peak. 
 
We also examined how NNRTI binding affects the different drug-resistant variants of 
RT181tfmF. In the presence of 5-fold excess of NVP, EFV, ETR and RPV, the spectra of 
RT181tfmF-V108I exhibit chemical shifts and linewidths similar to those of RT181tfmF (Figure 
6.4a,b). All bound resonances are significantly sharper (~125 Hz) than in the apo form (~500 
Hz). At 1:1 RT: NVP molar ratio, as expected, the ligand-free RT signal is still present, 
consistent with the 2-fold larger in EC50 value, compared to wt-RT [249]. RT181tfmF-K103N 
and RT181tfmF-E138K(p51) also exhibit similar changes in chemical shifts and linewidths, as 
seen with RT181tfmF upon NNRTI binding (Figure 6.4c,d; Table 6.1). Note that binding of 
NVP to RT181tfmF-K103N was not observed (Figure 6.4c). This agrees well with the much 
larger EC50 values reported in cell-based assays (> 1 µM) [58]. Taken together, upon NNRTI 
binding to RT, substantially narrower 19F signals are observed for the tfmF group at position 181, 
demonstrating that the NNRTI-binding pocket becomes confined and looked into a more rigid 
conformation. 
 RT127tfmF RT146tfmF RT181tfmF RT181tfmF- 
V108I 
RT181tfmF-
E138K(p51) 
RT181tfmF-K103N 
 ppm Hz ppm Hz ppm Hz ppm Hz ppm Hz ppm Hz 
Apo -61.5 100 ± 2 -60.2  
-62.0  
150 ± 85  
150 ± 5  
-60.8b   
 
500 ± 5  
 
-61.1b     
 
500 ± 5  
 
-60.8b    
 
600 ± 20  
 
-60.1     
 
300 ± 15  
 
EFV -61.5  100 ± 5 -60.2  
-61.8   
180 ± 1  
180 ± 2  
-60.3  
 
125 ± 2  -60.3  125 ± 5 -60.2  170 ± 5  -60.4  150 ± 2  
ETR     -60.3  125 ± 2 -60.3  125 ± 5 -60.2  125 ± 2  -60.4  145 ± 2  
RPV     -60.7  140 ± 2  -60.7  125 ± 5  -60.7  125 ± 5  -60.7  145 ± 2  
NVP   -60.2 
-61.9b 
 
180 ± 30 
200 ± 25 
 
-59.7  
-60.8b    
180 ± 5  
500 ± 10  
-59.7  
-61.1b    
125 ± 10  
400 ± 10   
-59.7  
-60.9b   
125 ± 10  
600 ± 15 
-60.1b   300 ± 20  
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Figure 6.4 1D 19F NMR spectra of RT181tfmF and several RT181tfmF mutants in the absence (black) and 
presence of NVP (pink), EFV (green), ETR (blue) and RPV (orange) 
a) Superposition of the 19F spectra of apo-RT181tfmF and the 19F spectra of RT181tfmF in the presence 
of each NNRTI, b) Superposition of the 19F spectra of apo-RT181tfmF-V108I and the 19F spectra of 
RT181tfmF in the presence of each NNRTI, c) Superposition of the 19F spectra of apo-RT181tfmF-K103N 
and the 19F spectra of RT181tfmF-K103N in the presence of each NNRTI,  d) Superposition of the 19F 
spectra of apo-RT181tfmF-E138K(p51) and the 19F spectra of RT181tfmF-E138K(p51) in the presence of 
each NNRTI. The 19F spectra in the presence of each NNRTI at 1:1 and 1:5 molar ratios are shown in 
light and dark colors, respectively. Chemical formulae for each inhibitor are depicted in the individual 
panels.  
 
6.3.5 NVP and EFV binding to RT146tfmF and mutants associated with drug resistance 
We also recorded 19F NMR spectra of RT146tfmF and its V108I and K103N mutants (Figure 
6.3b). The spectra of these mutants in the apo form (without inhibitor) are essentially identical to 
each other, demonstrating that the tfmF group in position 146 is not affected by amino acid 
changes at positions 103 and 108 that cause drug resistance. From the 19F NMR spectra of 
RT146tfmF and the mutants in the presence of NVP or EFV, it can be appreciated that saturation 
with EFV is essentially complete at 1:1 RT:EFV molar ratio (Figure 6.5, note that the panel of 
Figure 6.2b is included as the 2nd panel in Figure 6.5a for comparison). In contrast, with NVP, 
much higher concentrations are needed to reach saturation. As expected,[58] no NVP binding to 
RT146tfmF-K103N was detected. The spectra in the presence of NNRTIs exhibit two signals at 
approximately -62 ppm and -60 ppm, irrespective of the mutations (Table 6.2).  
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Table 6.2 19F Resonance frequencies and linewidths of mutants of RT146tfmFa 
 
 RT146tfmF- 
V108I 
RT146tfmF- 
K103N 
 ppm Hz ppm Hz 
Apo -60.1 
-62.1 
150 ± 30 
150 ± 5 
-60.1 
-62.1 
150 ± 30 
150 ± 5 
EFV -60.1 
-61.9b 
180 ± 5 
300 ± 15 
-60.1 
-61.9b 
180 ± 5 
260 ± 5 
NVP -60.2 
-61.9b 
 
180 ± 10 
200 ± 25 
 
-60.1 
-62.1 
150 ± 30 
150 ± 5 
a the upper limit of uncertainty in the linewidth was qualitatively estimated as described in Materials and Methods. 
b although the signal is not symmetric, the resonance frequency and linewidth extracted assuming a single peak. 
 
 

For RT146tfmF-V108I and RT146tfmF-K103N the EFV-bound signals (at 1:5 molar ratio) 
resonate at -62 ppm and are somewhat asymmetric, compared to that of RT146tfmF (Figure 
6.5). However, these differences are small and may reflect minor differences in dynamics in 
these mutants. Overall, all available data for RT146tfmF show that no significant effect is seen in 
the spectra when the drug resistant mutational changes are introduced into the protein, both in the 
apo- and NNRTI-bound forms. This observation is consistent with the location of residue 146 in 
the RT structure on the fingers subdomain, ~30 Å away from the NNRTI binding site (Figure 
6.1b).  
 81 
 
Figure 6.5 Superposition of 1D 19F NMR spectra for RT146tfmF 
a) RT146tfmF, b) RT146tfmF-V108I, and c) RT146tfmF-K103N, in the absence (black) and presence of 
NVP (pink) or EFV (green). The 19F spectra in the presence of each NNRTI at 1:1 and 1:5 molar ratios 
are shown in light and dark colors, respectively.  
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6.3.6 Sensing the NNRTI interaction in RT181tfmF and RT146tfmF using the tfmF 
probe. 
Given that residue 181 resides in the NNRTI binding site, extensive studies were carried out with 
different RT181tfmF variants. All chemical shifts and linewidths for these variants are 
summarized in Figure 6.6a,b. In the absence of inhibitors, the linewidths of the ligand-free 
signals are larger (Figure 6.6a) and the chemical shifts are diverse (Figure 6.6b). The chemical 
shifts of the NVP-, EFV-, ETR-, and RPV-bound RT181tfmF resonances are -59.7, -60.3, -60.3, 
-60.7 ppm, respectively, suggesting that different inhibitors create different chemical 
environments around the 181tfmF probe. Based on the linewidth data, although NNRTIs are 
chemically dissimilar, NVP, EFV, ETR, and RPV all seem to lock the NNRTI-binding pocket 
into a more rigid conformation (Figure 6.6a). For RT146tfmF no significant changes in 
resonance frequencies and linewidths in the apo- and NNRTI-bound forms among the variants 
are observed (Figure 6.6c and 6.6d).  
Furthermore, and most significantly, the inhibitor-bound chemical shifts of RT181tfmF 
resonances are specific for each inhibitor. Indeed, all RT variants, when complexed with NVP, 
exhibit the same chemical shift of -59.7 ppm. Likewise, the RPV-bound chemical shift is -60.7 
ppm and EFV- and ETR-bound chemical shifts are -60.3 ± .1 ppm. These data suggest that the 
differences in the environment of the 19F probe at position 181 in the apo-RT proteins become 
diminished upon inhibitor binding, resulting in a chemical environment determined by the 
specific inhibitor, presumably by rigidifying the NNRTI-binding pocket around the inhibitor.  
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Figure 6.6  Plots of linewidths and chemical shifts of the signals in the 19F spectra of RT181tfmF and 
RT146tfmF and the drug-resistant variants, respectively, in the absence and presence of each NNRTI. 
In a) and b), plots are shown for apo- and NNRTI-bound signals of RT181tfmF (o), RT181tfmF-K103N 
(x), RT181tfmF-V108I (), and RT181tfmF-E138K(p51) (). In c) and d), plots are shown for apo- and 
NNRTI-bound signals of RT146tfmF (o), RT146tfmF-K103N (x), and RT146tfmF-V108I (). Note that 
since the spectra of RT146tfmF and mutants thereof comprise two resonances at approximately at -62 
and -60 ppm, two sets of points are contained in the plots presented in c) and d). Values were obtained 
from the spectra provided in Figures 4 and 5. 
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6.4 DISCUSSION  
19F solution NMR experiments on site-specifically 19F labeled RT variants were preformed to 
assess the proteins' behavior in the absence and presence of several NNRTIs. The three singly 
fluorinated RT proteins, RT127tfmF, RT146tfmF and RT181tfmF exhibit distinct spectra, 
reflecting the different chemical environments surrounding the 19F probes.  For two 19F-labeled 
proteins, RT146tfmF and RT181tfmF, EFV binding clearly can be monitored by the probe. 
Interestingly, the spectrum of free RT181tfmF (Figure 6.2c) exhibits a very broad signal, 
incompatible with a single, narrow conformation of the protein, and suggests a very plastic, 
mobile environment that is sensed by the 19F nucleus. In the crystal structures of apo-RT and 
NNRTI-bound RT, two different conformations of tyrosine 181 are observed, and rotation of the 
side chain out of the NNRTI-binding pocket in the complex is necessary to accommodate 
inhibitor binding [36, 38, 44, 46, 49]. However, as described in the introduction, only limited 
data are available for apo-RT, in contrast to an abundance of data on ligand-bound RT. Since it is 
essential to have access to equivalent information for both apo- and ligand-bound forms in order 
to evaluate conformational changes between the two states, we studied RT in solution. The 
spectrum of ligand-free RT suggests that the NNRTI-binding site is highly plastic in the free 
enzyme, and not confined to a single, narrow conformation. Thus, the solution NMR results offer 
different, but complementary information to the crystallographic data. 
We also investigated the effect of drug-induced mutations on the chemical environment 
around the 19F probe at position 181 (RT181tfmF-V108I, RT181tfmF-K103N and RT181tfmF-
E138K(p51). Each mutation is located in a different position (Figure 6.1c). V108 is positioned 
behind residue Y188, and K103 (p51) and E138 (p51) are located at the entrance of the NNRTI-
binding site. Our NMR data show that amino acid changes at these sites affect the chemical 
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environment of the 19F probe at position 181, with the K103N change producing the greatest 
effects (Figure 6.3a). In particular, the narrow signal of RT181tfmF-K103N suggests that this 
mutation restricts the plasticity of the NNRTI-binding site. These results are consistent with 
previous studies, based on crystallographic and computational data, which suggest a “closed” 
form of the NNRTI-binding pocket in K103N RT [238, 250]. In contrast, 19F signals of the 
RT181tfmF-E138K and RT181tfmF-V108I variants are significantly broader, suggesting that 
they possess a more plastic NNRTI-binding site. Interestingly, the latter mutations are associated 
with the lower degree of NNRTI resistance [246, 248, 251]. 
Our NMR data also revealed remarkable changes in chemical shifts and linewidths of the 
RT181tfmF signal upon interactions with NNRTIs. Importantly, the dynamic behavior of the 181 
site is quenched upon EFV binding, consistent with previous results from HXMS experiments 
that showed higher protection for peptides 88-109 and 187-192 in the presence of EFV[231]. A 
similar effect is seen for NVP, ETR and RPV binding. We find that all the NNRTI-bound signals 
are narrower, indicating a significant reduction in the flexibility of the inhibitor-bound forms, 
compared to the apo-form (Figure 6.6a). Most interestingly, the chemical shifts of the different 
NNRTI-bound variants revealed an intriguing pattern: while the resonance frequencies of the 
ligand-free RT181tfmF variants, V108I, K103N and E138K(p51), are all different, compared to 
RT181tfmF, once a particular inhibitor is bound, these differences disappear. For all four protein 
complexes, essentially the same chemical shifts are noted for the inhibitor-bound proteins; thus, 
the NNRTI-bound shifts are characteristic for a particular inhibitor, irrespective of the presence 
of mutations that are associated with drug resistance. This suggests that it is the identity of the 
inhibitor, which ultimately determines the resonance frequencies of the tfmF probe at position 
181.  
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While it is possible that the fluorophenylalanine substitution for tyrosine at position 181 
may influence the conformation in NNRTI-binding site, this effect has to be very small, given 
that the binding affinities of EFV and NVP to RT181tfmF are consistent with reports in the 
literature [231]. In addition, the effects observed upon EFV binding when the tfmF probe resides 
at positions 127, 146, and 181 agree well with the distances between the 19F nucleus and the 
NNRTI binding site. Thus, observed 19F spectral changes upon NNRTI binding perhaps 
qualitatively reflect the native dynamics of individual sites. As described above, the 19F 
resonances of apo RT181tfmF and mutants thereof vary (Figure 6.3a).  
In summary, our data provide new insights into the dynamics of the NNRTI-binding site 
and suggest a mechanism of action for NNRTIs. Our results clearly demonstrate that the NNRTI-
binding site is highly plastic in the ligand-free enzyme, and that drug resistance mutants 
modulate this conformational plasticity. Importantly, NVP, EFV, ETR, and RPV all reduce the 
dynamics of RT in the NNRTI-binding site, and the NNRTI-bound chemical shifts are 
determined by the identity of the inhibitor. Furthermore, the present study demonstrates that 19F 
NMR can be used as an effective tool for examining ligand-protein interactions in cases where 
only small amounts of protein are available or limited solubility of protein or ligand exist.  
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7.0  SUMMARY 
To address the HIV-1 pandemic, significant efforts have been made to develop targeted 
therapeutics against the HIV-1 virus. As a result of multidisciplinary efforts and decades worth 
of research, 24 FDA approved drugs against HIV-1 are currently available. These inhibitors 
include NRTIs, NNRTIs, PI, FI, EI and INSTs. The use of these inhibitors as part of HAART 
treatment has greatly increased patient lifespan and quality of life. As a result, HIV-1 infection is 
now considered a manageable chronic condition, rather than a life-threatening disease [3]. Yet, 
despite current treatment efforts, resistance has been documented for all antiretroviral drug 
classes; therefore, new therapeutic regimens are needed as the virus continues to evolve and 
acquire resistance [2, 3, 30].  
Currently half of the FDA approved drugs used to treat HIV-1 infection target RT, an 
enzyme that produces viral DNA using genomic viral RNA as a template. Given RT’s essential 
role in the viral lifecycle it is still considered to be an attractive target for therapeutic intervention 
[4, 36]. To develop novel inhibitors with more favorable resistance profiles, it is important to 
gain a thorough understanding of RT, its structure, and mechanism of inhibitor action. Currently, 
there are over 200 X-ray structures of RT, including RT variants, and RT bound to different 
ligands in the PDB. These models have greatly contributed to the success of structure-based drug 
design and development of more potent HIV-1 drugs [3]. Although X-ray crystallography has 
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been invaluable for providing details of RT, studies by other methods are essential to obtain a 
true understanding of the protein in solution. 
Solution NMR is now considered a powerful and versatile tool for protein studies. 
Uniquely, NMR can be used to determine protein structures and/or obtain information on a select 
number of NMR observable probes. Recent advances in hardware, software, pulse sequence 
design, processing procedures and the ability to isotopically label proteins has placed NMR side-
by-side with X-ray crystallograhy. In this thesis, we used solution NMR to study the p66 
immature RT precursor, which so far has resisted crystallization, and used fluorine NMR to 
study RT-NNRTIs interactions in solution.  
Specifically, in chapter 4, we found that in the dimer p66 precursor, the RNH and thumb 
subdomains are folded and possess conformations very similar to those in mature RT. This 
finding suggests that maturation models which invoke a complete or predominantly unfolded 
RNH domain are unlikely. In chapter 5, we report the solution NMR structure of the isolated 
thumb subdomain of HIV-1 reverse transcriptase (RT). A detailed comparison of the current 
structure with dozens of the highest resolution crystal structures of this domain in the context of 
the full-length enzyme reveals that the overall structures are very similar, with only two regions 
exhibiting local conformational differences. Taken together, we show that the thumb subdomains 
in mature RT and the p66 immature precursor are independent units that can fold autonomously 
and exhibit very similar structures, whether in isolation or present in its two different natural 
structural contexts (p51 or p66). Finally, in chapter 6 we investigated RT-NNRTI interactions 
by 19F NMR, using singly 19F labeled RT proteins. Comparison of 19F chemical shifts of 
fluorinated RT and drug-resistant variants revealed that the fluorine resonance is a sensitive 
probe for identifying mutation-induced changes in the enzyme.  Our data show that in the 
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unliganded enzyme, the NNRTI-binding pocket is highly plastic and not locked into a single 
conformation. Upon inhibitor binding, the binding pocket rigidifies.  
 In this thesis I show that solution NMR can be a powerful tool to study proteins that 
resist crystallization, and provide important unique information on protein structure and 
dynamics.  
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